

07/28/00
JC6893 U.S. PTO

0 / - 51 - 00
A

DOCKET NO. : UPN-3832

PATENT

JC682 U.S. PTO
09/627775
07/28/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Mark I. Greene, Ramachandran Murali,
Kazuhiro Aoki, William Carle Horne and
Roland Baron

Serial No.: Not yet assigned

Group Art Unit: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

For: METHODS OF INHIBITING OSTEOCLASTOGENESIS

EXPRESS MAIL LABEL NO: EL531276548US
DATE OF DEPOSIT: July 28, 2000

Box Patent Application
 Provisional Design

Assistant Commissioner for Patents
Washington DC 20231

Sir:

PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find

A Utility Patent Application under 37 C.F.R. 1.53(b).

It is a continuing application, as follows:

continuation divisional continuation-in-part of prior application number

A Provisional Patent Application under 37 C.F.R. 1.53(c).

A Design Patent Application (submitted in duplicate).

Including the following:

- Provisional Application Cover Sheet.
- New or Revised Specification, including pages 1 to 63 containing:
- Specification
- Claims
- Abstract
- Substitute Specification, including Claims and Abstract.
- The present application is a continuation application of Application No. _____ filed _____. The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter.
- The present application is a continuation application of Application No. _____ filed _____, which in turn is a continuation-in-part of Application No. _____ filed _____. The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions included in the present application, the present application includes no new matter in relation to the parent application.
- A copy of earlier application Serial No. _____ Filed _____, including Specification, Claims and Abstract (pages 1 - @@), to which no new matter has been added TOGETHER WITH a copy of the executed oath or declaration for such earlier application and all drawings and appendices. Such earlier application is hereby incorporated into the present application by reference.
- Please enter the following amendment to the Specification under the Cross-Reference to Related Applications section (or create such a section) : "This Application:
 is a continuation of is a divisional of claims benefit of U.S. provisional Application Serial No. _____ filed _____

-
-
-
- Signed Statement attached deleting inventor(s) named in the prior application.
- A Preliminary Amendment.
- 1 Sheet of a Formal Informal Drawing.
- Petition to Accept Photographic Drawings.
- Petition Fee
- An Executed Unexecuted Declaration or Oath and Power of Attorney.
- An Associate Power of Attorney.
- An Executed Copy of Executed Assignment of the Invention to _____
- A Recordation Form Cover Sheet.
- Recordation Fee - \$40.00.
- The prior application is assigned of record to _____
- Priority is claimed under 35 U.S.C. § 119 of Patent Application No. _____ filed _____ in _____ (country).
- A Certified Copy of each of the above applications for which priority is claimed:
- is enclosed.
- has been filed in prior application Serial No. _____ filed _____.
- An Executed or Copy of Executed Earlier Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27
- is enclosed.
- has been filed in prior application Serial No. _____ filed _____, said status is still proper and desired in present case.

- Diskette Containing DNA/Amino Acid Sequence Information.
- Statement to Support Submission of DNA/Amino Acid Sequence Information.
- The computer readable form in this application _____, is identical with that filed in Application Serial Number _____, filed _____. In accordance with 37 CFR 1.821(e), please use the first-filed, last-filed or only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application, included in a separately filed preliminary amendment for incorporation into the specification.
- Information Disclosure Statement.
 Attached Form 1449.
 Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- A copy of Petition for Extension of Time as filed in the prior case.
- Appended Material as follows: _____

- Return Receipt Postcard (should be specifically itemized).
- Other as follows: _____

FEE CALCULATION:

- Cancel in this application original claims _____ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)


	SMALL ENTITY		NOT SMALL ENTITY	
	RATE	Fee	RATE	Fee
PROVISIONAL APPLICATION	\$75.00	\$	\$150.00	\$
DESIGN APPLICATION	\$155.00	\$	\$310.00	\$
UTILITY APPLICATIONS BASE FEE	\$345.00	\$345.00	\$690.00	\$
UTILITY APPLICATION; ALL CLAIMS CALCULATED AFTER ENTRY OF ALL AMENDMENTS				
No. Filed	No. Extra			
TOTAL CLAIMS	48- 20 =	28	\$9 each	\$252.00
INDEP. CLAIMS	3- 3 =	0	\$39 each	\$0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM	\$130	\$	\$260	\$
ADDITIONAL FILING FEE		\$		\$
TOTAL FILING FEE DUE		\$597.00		\$

- A Check is enclosed in the amount of \$ 597.00.
- The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.
- The foregoing amount due.
- Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).
- The issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance.
- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-

identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: 7/28/2000



Gwilym J. O. Attwell
Registration No. 45,449

Woodcock Washburn Kurtz
Mackiewicz & Norris LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 1997 WWKMN

METHODS OF INHIBITING OSTEOCLASTOGENESIS

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application U.S. Application Serial No. 60/146,090, filed July 28, 1999, which is hereby incorporated by reference in its entirety.

5 ACKNOWLEDGMENT OF GOVERNMENT RIGHTS

The present invention was made under Grant EY09332 from the National Institutes of Health. The Government may have certain rights to the invention.

FIELD OF THE INVENTION

The present invention relates to the methods of down-modulating

- 10 osteoclastogenesis activity, thereby inhibiting bone matrix erosion and thus preventing bone loss and treating bone diseases. The present invention also relates to peptides and peptide analogues which inhibit TNF binding to its cellular receptors, methods of designing similar peptides and peptide analogues, and methods of using such compounds to inhibit the biological activities of TNF particularly those activities relating to bone
15 resorption, thereby antagonizing its undesirable clinical effects.

BACKGROUND OF THE INVENTION

Osteoclasts are large multinuclear cells which function to erode bone matrix. They are related to macrophage and other cells that develop from monocyte cells. Like macrophage, osteoclasts are derived from haematopoietic progenitor cells.

Bone matrix erosion is a normal process which occurs in coordination with

- 5 bone matrix formation, a process in which osteoblasts are involved. Essentially, osteoblasts erode bone matrix and tunnel into bone while osteoblasts follow, line the walls of the tunnel and form new bone matrix. Typically, in a normal adult, about 5-10% of bone is replaced by these processes annually.

- Bone diseases such as osteoporosis and Paget's disease are characterized by
10 a loss of bone. Similarly, metastatic bone disease, rheumatoid arthritis, and periodontal bone disease are also characterized by bone loss. In many cases, bone loss leads to fractures in patients. In addition to pain and suffering, patients become physically impaired which often leads to complications having negative consequences on patient health and quality of life. Moreover, the economic costs attributable to these diseases are
15 tremendous.

- Receptors and ligands of the Tumor Necrosis Factor (TNF) family have recently been shown to play an essential part in the differentiation and activity of osteoclasts and therefore play a role in bone resorption. On the one hand, TNF- α is known to promote osteoclastogenesis, the generation of osteoclasts. On the other hand, a TNF-like molecule present on and/or secreted by osteoclasts and stromal cells, referred to interchangeably in the field and herein as "Receptor activator of NF- κ B ligand", (RANKL), "Osteoclast differentiation factor" (ODF), "Osteoprotegerin ligand" (OPGL), and "TNF-related activation-induced cytokine" (TRANCE), interacts with a TNF-receptor-like molecule, referred to in the field and herein as "Receptor activator of NF- κ B ligand",
20 (RANK), which, present in the membranes of osteoclast precursors and mature osteoclasts, regulates osteoclastogenesis and the resorbing activity of mature osteoclasts. The utilization of TNF- α antagonists, such as a monoclonal antibodies, for therapeutic purposes, has proven difficult, however, because of immunity to the large molecule, and limited entry into some specialized compartments of the body. Suda, *et al.* (Endocrine
25 Reviews 20(3):345-357, 1999), which is incorporated herein by reference, describe
30 osteoclast differentiation and function. Filvaroff, E and R. Derynck (Curr. Biol. 8:R679-

R682, 1998) which is incorporated herein by reference, refer to bone remodeling and a signaling system for osteoclast regulation.

Thus, there is a need for methods of regulating osteoclastogenesis and the resorbing activity of mature osteoclasts. There is also a need for methods of preventing
5 bone loss and treating bone diseases.

SUMMARY OF THE INVENTION

The present invention relates to methods of inhibiting osteoclastogenesis and the resorbing activity of mature osteoclasts. According to the present invention, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclast bone erosion activity
10 is administered to a patient.

The present invention relates to methods of treating patients who have diseases characterized by bone loss. According to the present invention, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to a patient.

15 The present invention relates to pharmaceutical compositions which comprise a TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis.


The present invention relates to methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual comprising the step of administering to the individual an amount of a TRANCE/RANK inhibitor
20 effective to modulate dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.

The present invention relates to the use of peptides and peptide analogues designed from a binding loop of a TNF-R superfamily member. In particular, it relates to the use of peptides and peptide analogues designed from three binding loops of TNF-R.
25 More specifically, the invention relates to peptides and peptide analogues which inhibit activities relating to bone resorption.

Generally, compounds used in the present invention are cyclic peptides or peptide analogues which are modified at their termini with hydrophobic moieties. In embodiments wherein the compound is a peptide, the peptide corresponds in primary
30 sequence to a binding loop of a member of the TNF-R superfamily or a portion thereof. In

- a preferred embodiment, the peptide used in the invention corresponds in primary sequence to a binding loop of TNF-R p55 or a portion thereof. In certain embodiments, one or more amino acid residues within the peptide are substituted with other amino acid residues. Typically, such amino acid substitutions are conservative, *i.e.*, the amino acid
- 5 residues are replaced with other amino acid residues having similar physical and/or chemical properties. In embodiments wherein the compound is a peptide analogue, the analogue is obtained by replacing at least one amide linkage in the peptide with a substituted amide or an isostere of amide.

In an illustrative embodiment, a compound used in the invention has the
10 following formula:



(I)

wherein:

- AC is a peptide of 3-18 amino acid residues which corresponds in primary sequence to a binding loop of a TNF-R superfamily member, and which may optionally
15 contain one or more conservative amino acid substitutions, or an analogue thereof wherein at least one amide linkage is replaced with a substituted amide or an isostere of amide;

AB₁ is a moiety having a first functional group capable of forming a covalent linkage with one terminus of AC, a second functional group capable of forming a covalent linkage with AB₂ and a third functional group capable of forming a covalent
20 linkage with AA₁;

AB₂ is a moiety having a first functional group capable of forming a covalent linkage with the second terminus of AC, a second functional group capable of forming a covalent linkage with AB₁ and a third functional group capable of forming a covalent linkage with AA₂;

AA₁ is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB₁;

AA₂ is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB₂;

- 5 “=” is a covalent linkage; and
“≡” is a covalent linkage.

In a preferred embodiment of the compounds of formula (I), AC is a peptide which corresponds in primary sequence to a binding loop of TNF-R p55 and which optionally may contain one or more conservative amino acid substitutions, or an analogue
10 thereof. In a particularly preferred embodiment, the peptides and peptide analogues specifically inhibit osteoclastogenesis.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the sequence alignment of amino acids in certain extracellular Cys-rich domains of TNF-R superfamily members: TNF-R p55 (SEQ ID NO:1), TNF-R p 75 (SEQ ID NO:2), TNF-R-rp (SEQ ID NO: 3), NGF-R p75 (SEQ ID NO: 4), CD27 (SEQ ID NO:5), CD30 (proximal) SEQ ID NO:6), CD30 (distal) (SEQ ID NO:7), CD40 (SEQ ID NO:10), and 4-IBB (SEQ ID NO:11).

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The invention provides methods for treating individuals that have diseases
20 characterized by bone loss. TRANCE/RANK inhibitors are administered to the individual in an amount effective to inhibit osteoclastogenesis and/or osteoclast function and thereby reduce bone loss, *i.e.* a therapeutically effective amount.

The invention also provides novel therapeutic pharmaceutical compositions for treating diseases characterized by bone loss. The pharmaceutical compositions
25 comprise a therapeutically effective amount of TRANCE/RANK inhibitors and a pharmaceutically acceptable carrier or diluent. In preferred embodiments, the pharmaceutical compositions are injectable pharmaceutical compositions, *i.e.* they are

sterile, pyrogen-free, free of particulate matter, essentially isotonic, and are otherwise suitable for injection into humans.

As used herein, the term “TRANCE/RANK inhibitors” refers to peptides and peptide analogues which inhibit osteoclastogenesis and/or osteoclast function.

- 5 TRANCE/RANK inhibitors can function as an antagonist of the cellular receptor RANK by inhibiting TRANCE/RANK.

As used herein, the term “diseases characterized by bone loss” is meant to refer to diseases, conditions, disorders and syndromes which have as a symptom or pathology a decrease in bone mass or density. Examples of diseases characterized by bone
10 loss include, but are not limited to, osteoporosis, Paget’s disease, metastatic bone disease, rheumatoid arthritis and periodontal bone disease.

As used herein, the term “bone resorption” refers to the undesired loss of bone caused at least in part by osteoclast activity.

- As used herein, the term "therapeutically effective amount" is meant to refer
15 to an amount of a compound which produces a medicinal effect observed as reduction in the rate of bone loss in an individual when a therapeutically effective amount of a compound is administered to an individual who is susceptible to or suffering from a disease characterized by bone loss. Therapeutically effective amounts are typically determined by the effect they have compared to the effect observed when a composition
20 which includes no active ingredient (*i.e.* a control) is administered to a similarly situated individual.

- As used herein, the term “inhibit” means to decrease the amount, quality, or effect of a particular activity and is used interchangeably with the terms “reduce”, “minimize”, and “lessen” and refers to, for example, the reduction of osteoclast bone
25 erosion activity caused by the administration of a therapeutically effective amount of the compounds of the present invention to a patient.

- As used herein, the term “alkyl” refers to a saturated branched, straight chain or cyclic hydrocarbon group. Typical alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl, and the like. In
30 preferred embodiments, the alkyl groups are (C₁-C₅) alkyl, with (C₁-C₃) being particularly preferred.

As used herein, the term “substituted alkyl” refers to an alkyl group wherein one or more hydrogen atoms are each independently replaced with other substituents.

As used herein, the term “alkenyl” refers to an unsaturated branched, straight chain or cyclic hydrocarbon group having at least one carbon-carbon double bond. The group 5 may be in either the *cis* or *trans* conformation about the double bond(s). Typical alkenyl groups include, but are not limited to, ethenyl, propenyl, isopropenyl, butenyl, isobut enyl, tert-but enyl, pentenyl, hexenyl and the like. In preferred embodiments, the alkenyl group is (C₁-C₆) alkenyl, with (C₁-C₃) being particularly preferred.

As used herein, the term “alkynyl” refers to an unsaturated branched, straight chain 10 or cyclic hydrocarbon group having at least one carbon-carbon triple bond. Typical alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, isobutynyl, pentynyl, hexynyl and the like. In preferred embodiments, the alkynyl group is (C₁-C₆) alkynyl, with (C₁-C₃) being particularly preferred.

As used herein, the term “substituted alkynyl” refers to an alkynyl group wherein 15 one or more hydrogen atoms are each independently replaced with other substituents.

As used herein, the term “alkoxy” refers to an -OR group, where R is alkyl, alenyl or alkynyl, as defined above.

As used herein, the term “aromatic moiety” refers to a moiety having an unsaturated cyclic hydrocarbon group which has a conjugated (4n=2) π electron system. 20 typical aromatic moieties include, but are not limited to, benzene, naphthalene, anthracene, azulene, indacene, and the like. In preferred embodiments, the aromatic moiety contains 5-20 carbons in the ring system, with 5-10 carbon atoms being particularly preferred.

As used herein, the term “substituted aromatic moiety” refers to an aromatic moiety wherein one or more hydrogen atoms are each independently replaced with other 25 substituents.

As used herein, the term “heteroaromatic moiety” refers to an aromatic moiety wherein one or more of the ring carbon atoms is replaced with another atom such as N, O or S. Typical heteroaromatic moieties include, but are not limited to, pyran, pyrazole, pyridine, pyrrolidine, pyrazine, pyridazine, pyrimidine, pyrrolizine, quinazoline, quinoline, 30 quinolizine, quinoxaline, selenophene, thiophene, tellurophene, xanthene and the like.

As used herein, the term “substituted heteroaromatic moiety” refers to a

heteroaromatic moiety wherein one or more hydrogen atoms are each independently replaced with other substituents.

Applicants have discovered that the peptides described *infra* are useful to inhibit osteoclastogenesis and/or osteoclast function. By inhibiting osteoclastogenesis and/or 5 osteoclast function, bone erosion can be minimized or even prevented, and bone loss can be reduced. Patients suffering from diseases characterized by bone loss can be treated by administering an amount of compound effective to inhibit osteoclastogenesis and/or osteoclast function. In addition, patients identified as being susceptible to diseases characterized by bone loss can be prophylactically treated by administering an amount of 10 compound effective to inhibit osteoclastogenesis and/or osteoclast function.

Individuals who have a disease characterized by bone loss can be identified by those having ordinary skill in the art by well known diagnostic means and criteria.

Individuals who are susceptible to a disease characterized by bone loss can be identified by those having ordinary skill in the art based upon family medical history and/or the presence 15 of genetic markers or genes associated with a disease characterized by bone loss.

According to the invention, TRANCE/RANK inhibitors useful in the invention are compounds described *infra* such as peptides and peptide analogues designed from a binding loop of a TNF-R superfamily member which function to inhibit osteoclastogenesis and/or osteoclast function. Such compounds may be produced by the methods described 20 *infra* or by other techniques well known to those skilled in the art.

According to the invention, TRANCE/RANK inhibitors useful in the invention to treat diseases characterized by bone loss may be formulated and administered in the manner taught *infra*, or by other techniques well known to those skilled in the art.

According to the invention, TRANCE/RANK inhibitors useful in the invention to 25 treat diseases characterized by bone loss may be formulated and administered in the manner taught *infra*, or by other techniques well known to those skilled in the art. Some preferred dosages range from 1nM to 500mM. Some preferred dosages range from 1mM to 500mM. Some preferred dosages range from 1mg to 500 mg. Some preferred dosages range from 1000mg to 3000 mg. Some preferred dosages range from 1500 mg to 2500 30 mg. According to the invention, TRANCE/RANK inhibitors are administered one to four times per day.

Pharmaceutical compositions according to the present invention comprise TRANCE/RANK inhibitors formulated in therapeutically effective doses. In some embodiments, the pharmaceutical composition is sterile and pyrogen free.

- Other aspects of the present invention include the use of TRANCE/RANK-
5 inhibitors in methods involving other cell types in which TRANCE/RANK-mediated signaling is involved in cell development and/or activity. Such cell types include antigen presenting cells such as dendritic cells and lymphocytes. Anderson *et al.* (*Nature* 390:175-179, 1997) refer to the RANK/RANKL in T cells and dendritic cells. Similarly, Kong *et al.* (*Immunol. and Cell Biology* 77:188-193, 1999) refer to osteoprotegerin ligand
10 as a common link between osteoclastogenesis, lymph node formation and lymphocyte development. In addition, Wong *et al.* (*J. Leukocyte Biology* 65:715-724, 1999) refer to TRANCE as regulating dendritic cell and osteoclast function. TRANCE/RANK inhibitors formulated in effective doses as described *supra* can be used to modulate dendritic cell maturation and function, T cell proliferation and CD40 receptor systems.

- 15 TNF exerts its biological activities by binding to two TNF-R: p55 and p75. A comparison of these receptors with several other cell surface receptors revealed certain shared structural features that led to their classification as a superfamily (Beutler *et al.*, *Science* 264:667, 1994). The TNF-R superfamily members possess characteristic extracellular Cys-rich domains, yet share only about 25% sequence homology. There are
20 at least ten members in this superfamily, including: TNF-R p55 and p75, TNF-R related protein (rp), CD40, Fas antigen (CD95), low-affinity nerve growth factor receptor (p74), CD27, CD30, 4-1BB and OX40 (Beutler *et al.*, *Ann. NY Acad. Sci.* pp. 118-133, 1994; Gruss and Dower, *Cytokines and Mol. Ther.* 1:75-105, 1995).

- Loops and turns in many proteins have been shown to play functionally important
25 roles in protein-protein interactions. In a specific embodiment illustrated by way of examples, *infra*, cyclic peptides were designed from three binding loops of TNF-R p55 which inhibited the binding of TNF to its cellular receptors. In particular, peptides designed from loop 1 of domain 3 exhibited the strongest inhibitory activities. When a peptide designed from this binding loop was used in combination with peptides designed
30 from two other loops, no further increase in inhibitory effects were observed, indicating that loop 1 of domain 3 is a dominate ligand binding site in TNF-R.


Based on this finding, corresponding regions of other TNF-R superfamily members from which inhibitory peptides and peptide analogues can be designed are readily identified by amino acid sequence alignment with the three specific binding sites of TNF-R p55 (Fig. 1). Since the dominate binding site of TNF-R p55 falls within amino acid residues #119 to 136, which sequence starts and ends with Cys, the same region in each TNF-R superfamily member may be used to design peptides and peptide analogues that are within the scope of the present invention. In cases where the regions do not start or end with Cys, the region may extend to then next Cys. For example, the corresponding region in Fas is deleted, and thus this region in starts at residue #97 and ends with #143. In the case of NGF-R, the region ends at the Cys at position at 135. Additionally, residues 74-81 and 97-110 may also be used to design additional peptides and peptide analogues within the scope of the present invention. Such compounds are then cyclized and modified at their termini with hydrophobic moieties as described in greater detail below.

Peptides and peptide analogues designed from binding loops of a TNF-R superfamily member

Generally, a compound used in the present invention is a cyclic peptide or peptide analogue, such as those disclosed in U.S. Application Serial No. 60/146,090, filed July 28, 1999, which is hereby incorporated by reference in its entirety. The peptide or peptide analogue is modified at its termini with hydrophobic moieties. In embodiments wherein the compound is a peptide, the peptide corresponds in primary sequence to a binding loop of a member of the TNF-R superfamily of a portion thereof. In a preferred embodiment, the peptide corresponds in primary sequence to a binding loop of TNF-R p55 or a portion thereof. In certain embodiments, one or more amino acid residues within the peptide are substituted with other amino acid residues. Typically, such amino acid substitutions are conservative, *i.e.*, the amino acid residues are replaced with other amino acid residues having physical and/or chemical properties similar to the residues they are replacing. Preferably, conservative amino acid substitutions are those wherein an amino acid is replaced with another amino acid encompassed within the same designated class, as will be described more thoroughly below. In embodiments wherein the compound is a peptide analogue, the analogue is obtained by replacing at least one amide linkage in the peptide

with a substituted amide or an isostere of amide.

In an illustrative embodiment, a compound used in the invention has the following formula:



(I)

5 wherein:

AC is a peptide of 3-18 amino acid residues, preferably 5-8 amino acid residues, which corresponds in primary sequence to a binding loop of a TNF-R and which may optionally contain conservative amino acid substitutions, or an analogue thereof wherein at least one amide linkage is replaced with a substituted amide or an isostere of amide;

10 AB₁ is a moiety having a first functional group capable of forming a covalent linkage with one terminus of AC, a second functional group capable of forming a covalent linkage with AB₂, and a third functional group capable of forming a covalent linkage with AA₁;

15 AB₂ is a moiety having a first functional group capable of forming a covalent linkage with the second terminus of AC, a second functional group capable of forming a covalent linkage with AB₁ and a third functional group capable of forming a covalent linkage with AA₂;




AA₁ is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB₂;

20 AA₂ is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB₁;

“=” is a covalent linkage; and

“≡” is a covalent linkage.

More specifically, the compounds of the invention are illustrated by three specific
25 embodiments having the following formulae:



The designation X_n in each case represents an amino acid at the specified position in the
5 compound. Similarly, the designation Z_n represents an amino acid or other moiety which
is capable of forming covalent linkages with other Z_n , such as disulfide bridges.
The amino acid residues denoted by X_n or Z_n may be the genetically encoded L-amino

acids, naturally occurring non-genetically encoded L-amino acids, synthetic L-amino acids or D-enantiomers of all of the above. The amino acid notations used herein for the twenty genetically encoded L-amino acids and common non-encoded amino acids are conventional and are as follows:

	Amino Acid	One-Letter Symbol	Common Abbreviation
5	Alanine	A	Ala
	Arginine	R	Arg
	Asparagine	N	Asn
	Aspartic acid	D	Asp
10	Cysteine	C	Cys
	Glutamine	Q	Gln
	Glutamic acid	E	Glu
	Glycine	G	Gly
	Histidine	H	His
15	Isoleucine	I	Ile
	Leucine	L	Leu
	Lysine	K	Lys
	Methionine	M	Met
	Phenylalanine	F	Phe
20	Proline	P	Pro
	Serine	S	Ser
	Threonine	T	Thr
	Tryptophan	W	Trp
	Tyrosine	Y	Tyr
25	Valine	V	Val
	β -alanine		bAla
	2,3-diaminopropionic acid		Dpr
	- α -aminoisobutyric acid		Aib

	N-Methylglycine (sarcosine)	MeGly
	Ornithine	Orn
	Citrulline	Cit
5	t-buylalanine	t-Bua
	t-butylglycine	t-Bug
	N-methylisoleucine	Melle
	phenylglycine	Phg
	cyclohexylalanine	Cha
10	Norleucine	Nle
	naphthylalanine	Nal
	Pyridylalanine	
	3-benzothienyl alanine	
	4-chlorophenylalanine	Phe(4-Cl)
15	2-fluorophenylalanine	Phe(2-F)
	3-fluorophenylalanine	Phe(3-F)
	4-fluorophenylalanine	9
	Penicillamine	Pen
20	1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid	Tic
	β -thienylalanine	Thi
	Methionine sulfoxide	MSO
	Homoarginine	hArg
25	N-acetyl lysine	AcLya
	2,4-diamino butyric acid	Dbu
	p-aminophenylalanine	Phe(pHN ₂)
	N-methylvaline	MeVal
	Homocysteine	hCys

Homoserine		hSer
ϵ -amino hexanoic acid		Aha

The compounds used in the invention are partially defined in terms of amino acid residues of designated classes. The amino acids may be generally categorized into three
 5 main classes: hydrophilic amino acids, hydrophobic amino acids and Cysteine-like amino acids, depending primarily on the characteristics of the amino acid side chain. These amino classes may be further divided into subclasses. Hydrophilic amino acids include amino acids having acidic, basic or polar side chains and hydrophobic amino acids including amino acids having aromatic or apolar side chains. Apolar amino acids ma be
 10 further subdivided to include, among others, aliphatic amino acids. The definitions of the classes of amino acids as used herein are as follows:

“Hydrophobic Amino Acid” refers to an amino acid having a side chain that is uncharged at physiological pH and that is repelled by aqueous solution. Examples of genetically encoded hydrophobic amino acids include Ile, Leu and Val. Examples of non-
 15 genetically encoded hydrophobic amino acids include t-BuA.

“Aromatic Amino Acid” refers to a hydrophobic amino acid having a side chain containing at least one ring having a conjugated π -electron system (aromatic group). The aromatic group may be further substituted with substituent groups such as alkyl, alkenyl, alkynyl, hydroxyl, sulfanyl, nitro and amino groups, as well as others. Examples of genetically encoded aromatic amino acids include phenylalanine, tyrosine and tryptophan.
 20 Commonly encountered non-genetically encoded aromatic amino acids include phenylglycine, 2-naphthylalanine, β -2-thienylalanine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 4-chloro-phenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine and 4-fluorophenylalanine.

25 “Apolar Amino Acid” refers to a hydrophobic amino acid having a side chain that is generlaly uncharged at physiological pH and that is not polar. Examples of genetically encoded apolar amino acids include glycine, proline and methionine. Examples of non-encoded apolar amino acids include Cha.

“Aliphatic Amino Acid” refers to an apolar amino acid having a saturated or
 30 unsaturated straight chain, branched or cyclic hydrocarbon side chain. Examples of

genetically encoded aliphatic amino acids include Ala, Leu, Val and Ile. Examples of non-encoded aliphatic amino acids include Nle.

- “Hydrophilic Amino Acid” refers to an amino acid having a side chain that is attracted by aqueous solution. Examples of genetically encoded hydrophilic amino acids 5 include Ser and Lys. Examples of non-encoded hydrophilic amino acids include Cit and hCys.

- “Acidic Amino Acid ” refers to a hydrophilic amino acid having a side chain pK value of less than 7. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Examples of genetically encoded acidic 10 amino acids include aspartic acid (aspartate) and glutamic acid (glutamate).

- “Basic Amino Acid” refers to a hydrophilic amino acid having a side chain pK value of greater than 7. Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion. Examples of genetically encoded basic amino acids include arginine, lysine and histidine. Examples of non-genetically 15 encoded basic amino acids include the non-cyclic amino acids ornithine, 2, 3-diaminopropionic acid, 2,4-diaminobutyric acid and homoarginine.

- “Polar Amino Acid” refers to a hydrophilic amino acid having a side chain that is uncharged at physiological pH, but which has a bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms. Examples of 20 genetically encoded polar amino acids include asparagine and glutamine. Examples of non-genetically encoded polar amino acids include citrulline, N-acetyl lysine and methionine sulfoxide.

- “Cysteine-Like Amino Acid” refers to an amino acid having a side chain capable of forming a covalent linkage with a side chain of another amino acid residue, such as a 25 disulfide linkage. Typically, cysteine-like amino acids generally have a side chain containing at least one thiol (SH) group. Examples of genetically encoded cysteine-like amino acids include cysteine. Examples of non-genetically encoded cysteine-like amino acids include homocysteine and penicillamine.

- As will be appreciated by those having skill in the art, the above classifications are 30 not absolute -- several amino acids exhibit more than one characteristic property, and can therefore be included in more than one category. For example, tyrosine has both an

aromatic ring and a polar hydroxyl group. Thus, tyrosine has dual properties and can be included in both the aromatic and polar categories. Similarly, in addition to being able to form disulfide linkages, cysteine also has apolar character. Thus, while not strictly classified as a hydrophobic or apolar amino acid, in many instances cysteine can be used to

5 confer hydrophobicity to a peptide.

Certain commonly encountered amino acids which are not genetically encoded of which the peptides and peptide analogues of the invention may be composed include, but are not limited to, β -alanine (B-Ala) and other omega-amino acids such as 3-aminopropionic acid (Dap), 2,3-diaminopropionic acid (Dpr), 4-aminobutyric acid and so

10 forth; α -aminoisobutyric acid (Aib); ϵ -aminohyxanoic acid (Aha); δ -aminovaleric acid (Ava); N-methylglycine or sarcosine (MeGly); ornithine (Orn); citrulline (Cit); t-butylalanine (t-BuA); t-butylglycine (t-BuG); N-methylisoleucine (MeIle); phenylglycine (phg); cyclohexylalanine (Cha); norleucine (Nle); 2-naphthylalanine (2-Nal); 4-chlorophenylalanine (Phe(4-Cl)); 2-fluorophenylalanine (Phe(2-F)); 3-fluorophenylalanine
15 (Phe(3-F)); 4-fluorophenylalanine (Phe(4-F)); penicillamine (Pen); 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic); β -2-thienylalanine (Thi); methionine sulfoxide (MOS); homoarginine (hArg); N-acetyl lysine (AcLys); 2,3-diaminobutyric acid (Dab); 2,3-diaminobutyric acid (Dbu); *p*-aminophenylalanine (Phe(*p*NH₂)); N-methyl valine (MeVal); homocysteine (hCys) and homoserine (hSer). These amino acids also fall
20 conveniently into the categories defined above.

The classifications of the above-described genetically encoded and non-encoded amino acids are summarized in Table 1, below. It is to be understood that Table 1 is for illustrative purposes only and does not purport to be an exhaustive list of amino acid residues which may comprise the peptides and peptide analogues described herein. Other

25 amino acid residues which are useful for making the peptides and peptide analogues described herein can be found, *e.g.*, in Fasman, 1989, CRC Practical Handbook of Biochemistry and Molecular Biology, CRC Press, Inc., and the references cited therein. Amino acids not specifically mentioned herein can be conveniently classified into the above-described categories on the basis of known behavior and/or their
30 characteristic chemical and/or physical properties as compared with amino acids specifically identified.

00000000000000000000000000000000

Table 1

<u>Classification</u>	<u>Genetically Encoded</u>	<u>Genetically Non-Encoded</u>
Hydrophobic		
5 Aromatic	F, Y, W	Phg, Nal, Thi, Tic, Phe(4-Cl), Phe(2-F), Phe(3-F), Phe(4-F); Pyridyl Ala, Benzothienyl Ala
10 Apolar	M, G, P	T-BuA, T-BuG, Melle, Nle,
Aliphatic	A, V, L, I Aib	MeVal, Cha, bAla, MeGly,
Hydrophilic		
15 Acidic	D, E	Dpr, Orn, hArg, Phe(<i>p</i> -NH ₂),
Basic	H, K, R	DBU, A ₂ BU
Polar	Q, N, S, T, Y	Cit, AcLys, MSO, hSer
Cysteine-Like	C	Pen, hCys, β-methyl Cys

20 The designation Z_n in each case represents an amino acid or other moiety capable of forming covalent linkages with other Z_n so as to allow cyclization of the peptide. Examples of amino acid residues which are capable of forming covalent linkages with one another include cysteine-like amino acids such as Cys, hCys, β-methyl Cys and Pen, which are capable of forming disulfide bridges with one another. Preferred cysteine-like amino 25 acid residues include Cys and Pen.

Amino acids used to cyclize a peptide need not be cysteine-like amino acids. Pairs of amino acids that have side chain functional groups capable of forming covalent linkages with one another can also be used. Such pairs of functional groups are known to those of skill in the art and include, *inter alia*, -COOH and -OH, -COOH and -NH₂, and -COOH 30 and -SH. Thus, pairs of amino acids that can be used to cyclize a peptide include, *inter alia*, Asp and Lys; Glu and Lys; Asp and Arg; Glu and Arg; Asp and Ser; Glu and Ser; Asp and Thr; Glu and Thr; Asp and Cys; and Glu and Cys. Other pairs of amino acids which can be used to cyclize the peptide will be apparent to those skilled in the art.

It will also be recognized that Z_n groups used to cyclize a peptide need not be 35 amino acids. Thus, Z_n may be any molecule having three functional groups -- one functional group capable of forming a covalent linkage with a terminus of the peptide, a

second functional group capable of forming a covalent linkage with the second functional group of another Z_n , and a third functional group capable of forming a covalent linkage with hydrophobic moieties B_n . Molecules having a suitable functional groups will be apparent to those skilled in the art. Examples of functional groups capable of forming a covalent linkage with the amino terminus of a peptide include carboxylic acids and esters. Examples of functional groups capable of forming a covalent linkage with the carboxyl terminus of a peptide include -OH, -SH, -NH₂ and -NHR where R is (C₁ - C₆) alkyl, (C₁ - C₆) alkenyl and (C₁ - C₆) alkynyl.

A variety of interlinkages useful to cyclize a peptide can be generated by reaction
10 between two Z_n. Z_n with functional groups suitable for forming such interlinkages, as well
as reaction conditions suitable for forming such interlinkages, will be apparent to those of
skill in the art. Preferably, the reaction conditions used to cyclize the peptides are
sufficiently mild so as not to degrade or otherwise damage the peptide. Suitable groups for
protecting the various functionalities as necessary are well known in the art (see, e.g., Green
15 & Wuts, 1991, 2nd ed., John Wiley & Sons NY), as are various reaction schemes for
preparing such protected molecules.

The destination B_n in each case represents a hydrophobic moiety. While not intending to be bound by any particular theory, it is believed that when placed in aqueous solution, these hydrophobic moieties interact so as to confer the peptide with structural stability. A significant hydrophobic interaction for conferring structural stability is thought to be stacking of aromatic rings. Thus, in a preferred embodiment, such B_n designates a peptide of 1-6 amino acids, at least one of which is an aromatic amino acid or an aromatic or heteroaromatic moiety. B_n may be illustrated as X₃₂-X₃₃-X₃₄-X₃₅-X₃₆-X₃₇ wherein X_n is an amino acid at least one of which is an aromatic amino acid. More preferably, X₃₂-X₃₃-X₃₄-X₃₅-X₃₆ are absent and X₃₇ is an aromatic amino acid. Suitable aromatic amino acids include Tyr, Phe and Trp, with Tyr and Phe being preferred. Suitable aromatic or heteroaromatic moieties include phenyl, naphthyl, purine, pyrimidine, and the like.

In the peptides of formulae (II) - (IV), the symbol “-” between amino acid residues X_n generally designates a backbone interlinkage. Thus, the symbol “-” usually designates an amide linkage (-C(O)-NH). It is to be understood, however, that in all of the peptides described in the specific embodiments herein, one or more amide linkages may optionally

be replaced with a linkage other than amide, preferably a substituted amide or an isostere of an amide linkage. Thus, while the various X_n have generally been described in terms of amino acids, one having skill in the art will recognize that in embodiments having non-amide linkages, the term "amino acid" refers to other bifunctional moieties having side-chain groups similar to the side chains of the amino acids. For example, in embodiments having non-amide linkages, the phrase "acidic amino acid" refers to a bifunctional molecule capable of forming the desired backbone interlinkages and which has a side chain group similar to the side chain of an acidic amino acid. Substituted amides generally include groups of the formula $-C(O)-NR$, where R is (C_1-C_6) alkyl, (C_1-C_6) alkenyl, (C_1-C_6) alkynyl, substituted (C_1-C_6) alkyl, substituted (C_1-C_6) alkenyl or substituted (C_1-C_6) alkynyl. Isosteres of amide generally include, but are not limited to, $-CH_2NH-$, $-CH_2S-$, $-CH_2CH_2$, $-CH=CH-$ (cis and trans), $-C(O)CH_2$ -and $-CH_2S-$.


Compounds having such linkages and methods for preparing such compounds are well-known in the art (*see, e.g.*, Spatola,, Vega Data 1 (3); 1983, for a general review); 15 Spatola, "Peptide Backbone Modifications" *In: Chemistry and Biochemistry of Amino Acids Peptides and Proteins* (Weinstein, ed.), Marcel Dekker, New York, p. 267 (general review) 1983; Morley, Trends Pharm. Sci. 1:463468, 1980; Hudson *et al.*, Int. J. Prot. Res. 14:177-185 (- CH_2NH -, $-CH_2CH_2$ -)1979; Spatola *et al.*, Life Sci. 38:1243-1249 (- CH_2-S), 1986; Hann, J. Chem. Soc. Perkin Trans. I. 1:307-314 (- $CH=CH$ -, cis and trans), 20 1982; Jennings-White *et al.*, Tetrahedron. Lett. 23:1392-1398 (- $COCH_2$); European Patent Application EP 45665 (1982) CA:97:39405 (- $CH(OH)CH_2$); Holladay *et al.*, Tetrahedron Lett. 24:4401-4404, 1983, (- $C(OH)CH_2$); and Hruby, Life Sci. 31:189-199, 1982 (- CH_2-S -).

As will be discussed in more detail below, the interlinkage designated by " \equiv "

25 between residues B_n and/or Z_n and/or X_n in the compounds of formulae (II) - (IV) may also be a linker. Typically, a linker is a bifunctional molecule that spaces one moiety from another. Such linkers, which may be flexible, semi-rigid or rigid, are well-known in the art and include polypeptides such as poly-Gly and poly-Pro, bifunctional hydrocarbons such as aminocaproic acid, δ - aminovaleric acid and β -alanine, carbohydrates, nucleic acids, and 30 the like.

In one specific illustrative embodiment, the compounds of formula (II) are defined

as follows:



wherein:

- B₁ and B₁₀ are each independently a peptide of 1-6 amino acids, at least one of
- 5 which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;
- Z₂ is a moiety that is capable of forming a covalent linkage with B₁, X₃ and Z₉;
- Z₉ is a moiety that is capable of forming a covalent linkage with B₁₀, X₈ and Z₂;
- X₃ is absent or a hydrophilic amino acid;
- X₄ is a hydrophobic amino acid;
- 10 X₅ is a hydrophilic amino acid;
- X₆ is a hydrophilic amino acid;
- X₇ is a hydrophobic or hydrophilic amino acid;
- X₈ is a hydrophobic or hydrophilic amino acid;
- . . . “-“ is an amide, substituted amide or an isostere of amide thereof;
- 15 “=“ is a covalent linkage; and
- “≡“ is a covalent linkage.

In a preferred embodiment of the invention, the compounds are those of formula (II) wherein:

- B₁ and B₁₀ are each independently a peptide of 1-3 amino acids, at least one of
- 20 which is an aromatic amino acid;
- Z₂ and Z₉ are each independently a Cys-like amino acid;
- X₃ is absent or an acidic amino acid;
- X₄ is an aromatic or apolar amino acid;
- X₅ is a polar amino acid;
- 25 X₆ is a polar amino acid;

- X₇ is an aromatic or polar amino acid;
X₈ is an aromatic, apolar or polar amino acid;
“-“ is an amide linkage;
“=” is a disulfide linkage; and
5 “≡” is an amide linkage.


In particularly preferred embodiment, the compounds used in the invention are those of formula (II) wherein:

- B₁ and B₁₀ are each independently Tyr or Phe;
Z₂ and Z₉ are each Cys;
10 X₃ is absent or Glu;
X₄ is Trp or Leu;
X₅ is Ser;
X₆ is Gln;
X₇ is Tyr or Asn;
15 X₈ is Tyr or Leu;
“-“ is an amide linkage;
“=” is a disulfide linkage; and
“≡” is an amide linkage.

Particularly preferred peptides used in the invention include the following:

- 20** YCELSQYLCY (SEQ ID NO:12)
YC WSQNLCY (SEQ ID NO:13)
YC WSQNYCY (SEQ ID NO:14)
YC WSQYLCY (SEQ ID NO:15)

In a second illustrative embodiment, the compounds of formula (III) are defined as
25 follows:



wherein:

B_{11} and B_{22} are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

- 5 Z_{12} is a moiety that is capable of forming a covalent linkage with B_{11} , X_{13} and Z_{21} ;
- Z_{21} is a moiety that is capable of forming a covalent linkage with B_{22} , X_{20} and Z_{12} ;
- X_{13} is absent or hydrophobic amino acid;
- X_{14} is absent or a hydrophilic amino acid;
- X_{15} is a hydrophilic or hydrophobic amino acid;

- 10 X_{16} is hydrophilic amino acid;
- X_{17} is absent or a hydrophobic amino acid;
- X_{18} is a hydrophilic amino acid;
- X_{19} is a hydrophilic amino acid;
- X_{20} is a hydrophilic amino acid;

- 15 “-“ is an amide, a substituted amide or an isostere of amide thereof;

In a preferred embodiment, the compounds are those of formula (III) wherein:

B_{11} and B_{22} are each independently a peptide of 1-3 amino acids, at least one of which is an aromatic amino acid;

Z_{12} and Z_{21} are each independently a Cys-like amino acid;

- 20 X_{13} is absent or an aromatic amino acid;
- X_{14} is absent or a polar amino acid;
- X_{15} is a basic, polar or apolar amino acid;

- X₁₆ is a polar amino acid;
X₁₇ is absent or an apolar amino acid;
X₁₈ is an acidic amino acid;
X₁₉ is a polar amino acid;
5 X₂₀ is a basic amino acid;
“-“ is an amide linkage;
“=“ is a disulfide linkage; and
“≡“ is an amide linkage.

- In particularly preferred embodiment, the compounds are those of formula (III),
10 wherein:
- B₁₁ and B₂₂ are each independently Tyr or Phe;
Z₁₂ and Z₂₁ are each Cys;
X₁₃ is absent or Phe;
X₁₄ is absent or Thr;
15 X₁₅ is Ala, Asn or Arg;
X₁₆ is Ser;
X₁₇ is absent or Val;
X₁₈ is Glu;
X₁₉ is Asn;
20 X₂₀ is Arg or His;
“-“ is an amide linkage;
“=“ is a disulfide linkage; and
“≡“ is an amide linkage.


Particularly preferred peptides used in the invention include the following:

- 25** YC FTASENH CY (SEQ. ID NO:16)
YC FTNSENH CY (SEQ. ID NO:17)
YC FTRSENH CY (SEQ. ID NO:18)
FC ASENH CY (SEQ. ID NO:19)
YC ASENH CY (SEQ. ID NO:20)
30 FC NSENH CY (SEQ. ID NO:21)
FC NSENR CY (SEQ. ID NO:22)

FC NSVENR CY

(SEQ. ID NO:23)

In a third illustrative embodiment, the compounds of formula (IV) are defined as follows:



5 wherein:

B_{23} and B_{33} are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

Z_{24} is a moiety that is capable of forming a covalent linkage with B_{23} , X_{25} and Z_{32} ;

Z_{32} is a moiety that is capable of forming a covalent linkage with B_{33} , X_{31} and Z_{24} ;

10 X_{25} is absent or a hydrophilic amino acid;

X_{26} is a hydrophilic amino acid;

X_{27} is a hydrophilic amino acid;

X_{28} is a hydrophobic amino acid;

X_{29} is a hydrophobic amino acid;

15 X_{30} is absent or a hydrophilic amino acid;

X_{31} is absent or a hydrophobic amino acid;

“-” is an amide, a substituted amide or an isostere of amide;

“≡” is a covalent linkage; and

“≡” is a covalent linkage.

20 In a preferred embodiment, the compounds are those of formula (IV) wherein:

B_{23} and B_{33} are each independently a peptide of 1-3 amino acids, at least one of which is a an aromatic acid;

Z_{24} and Z_{32} are each independently a Cys-like amino acid;

- X₂₅ is absent or a basic amino acid;
X₂₆ is a basic amino acid;
X₂₇ is an acidic amino acid;
X₂₈ is an apolar amino acid;
5 X₂₉ is an apolar amino acid;
X₃₀ is absent or a polar amino acid;
X₃₁ is absent or a apolar amino acid;
“-“ is an amide linkage;
“=” is a disulfide linkage; and
10 “≡” is an amide linkage.

In a particularly preferred embodiment, the compounds used in the invention or analogues thereof are those of formula (IV), wherein:

- B₂₃ an B₃₃ are each independently Tyr or Phe;
Z₂₄ and Z₃₂ are each Cys;
15 X₂₅ is absent or Arg;
X₂₆ is Lys;
X₂₇ is Glu;
X₂₈ is Leu, Pro or Met;
X₂₉ is Gly;
20 X₃₀ is absent or Gln;
X₃₁ is absent or Val;
“-“ is an amide linkage;
“=” is a disulfide linkage; and
“≡” is an amide linkage.

25 Particularly preferred peptides used in the invention include the following:

YC RKELGQV CY (SEQ. ID NO:24)
YC KEPGQ CY (SEQ. ID NO:25)
YC RKEMG CY (SEQ. ID NO:26)
FC RKEMG CY (SEQ. ID NO:27)

30 In all of the aforementioned embodiments of the invention, it is to be understood that the phrase “amino acid” also refers to bifunctional moieties having amino acid-like

side chains, as previously described.

Generally, active peptides or peptide analogues used in the invention are those that exhibit at least about 15% inhibition of TNF-R:TNF interactions as measured in *vitro* assays such as those described, *infra*. Preferably, active peptides used in the invention or

- 5 analogues thereof will exhibit at least about 20% to 50% or even 80% or more inhibition of TNF-R:TNF- α binding interactions.

Preparation Of Peptides And Peptide Analogues

Chemical Synthesis

- 10 The peptides used in the invention or analogues thereof, may be prepared using virtually any art-known technique for the preparation of peptides and peptide analogues. For example, the peptides may be prepared in linear or non-cyclized form using conventional solution or solid phase peptide syntheses and cyclized using standard chemistries. Preferably, the chemistry used to cyclize the peptide will be sufficiently mild
15 so as to avoid substantially degrading the peptide. Suitable procedures for synthesizing the peptides described herein as well as suitable chemistries for cyclizing the peptides are well known in the art.

- Formation of disulfide linkages, if desired, is generally conducted in the presence of mild oxidizing agents. Chemical, enzymatic or photolytic oxidation agents may be
20 used. Various methods are known in the art, including those described, for example, by Tam, J.P. *et al.*, *Synthesis* 955-957, **1979**; Stewart *et al.*, *Solid Phase Peptide Synthesis*. 2d Ed., Pierce Chemical Company Rockford, IL, **1984**; Ahmed *et al.*, *J. Biol. Chem.* 250:8477-8482, **1975**; and Pennington *et al.* *Peptides* 1990 164-166, Giralt and Andreu, Eds., ESCOM, **1991**; Leiden, The Netherlands. An additional alternative is described by
25 Kamber *et al.*, *Helv Chim Acta*, 63:899-915, **1980**. A method conducted on solid supports is described by Albericio, *Int.J. Peptide Protein Res.*, 26:92-97, **1985**. Any of these methods may be used to form disulfide linkages in the peptides of the invention. Preferred methods for effecting disulfide-bridge formation for the peptides described herein are provided in the examples.

- 30 Recombinant Synthesis

If the peptide is composed entirely of gene-encoded amino acids, or a portion of it is so composed, the peptide or the relevant portion may also be synthesized using conventional recombinant genetic engineering techniques. The isolated peptides, or segments thereof, are then condensed, and oxidized, as previously described, to yield a 5 cyclic peptide.

For recombinant production, a polynucleotide sequence encoding a linear form of the peptide is inserted into an appropriate expression vehicle, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence, or in the case of an RNA viral vector, the necessary elements for replication and 10 translation. The expression vehicle is then transfected into a suitable target cell which will express the linear form of the cyclic peptide. Depending on the expression system used, the expressed peptide is then isolated by procedures well-established in the art. Methods for recombinant protein and peptide production are well known in the art (see, e.g., Maniatis *et al.*, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, 15 N.Y., 1989; and Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, N.Y., 1989).

A variety of host-expression vector systems may be utilized to express the peptides described herein. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage DNA or plasmid DNA expression vectors 20 containing an appropriate coding sequence; yeast or filamentous fungi transformed with recombinant yeast or fungi expression vectors containing an appropriate coding sequence; insect cell systems infected with recombinant virus expression vectors (*e.g.*, baculovirus) containing an appropriate coding sequence; plant cell systems infected with recombinant virus expression vectors (*e.g.*, cauliflower mosaic virus or Tobacco mosaic virus) or 25 transformed with recombinant plasmid expression vectors (*e.g.*, Ti plasmid) containing an appropriate coding sequence; or animal cell systems.

The expression elements of the expression systems vary in their strength and specificities. Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, may 30 be used in the expression vector. For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage λ, plac, ptrp, ptac (ptrp-lac hybrid

- promoter) and the like may be used; when cloning in insect cell systems, promoters such as the baculovirus polyhedron promoter may be used; when cloning in plant cell systems, promoters derived from the genome of plant cells (*e.g.*, heat shock promoters; the promoter for the small subunit of RUBISCO; the promoter for the chlorophyll a/b binding protein) or from plant viruses (*e.g.*, the 35S RNA promoter of CaMV; the coat protein promoter of TMV) may be used; when cloning in mammalian cell systems, promoters derived from the genomes of mammalian cells (*e.g.*, metallothionein promoter) or from mammalian viruses (*e.g.*, the adenovirus late promoter; the vaccinia virus 7.5 K promoter) may be used; when generating cell lines that contain multiple copies of expression product,
- 5 10 SV40-, BPV- and EBV-based vectors may be used with an appropriate selectable marker.

In cases where plant expression vectors are used, the expression of sequences encoding the peptides of the invention may be driven by any of a number of promoters. For example, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV (Brissone *et al.*, Nature 310: 511-514, 1984), or the coat protein promoter of TMV (Takamatsu *et al.*, EMBO J., 6:307-311, 1987) may be used; alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi *et al.*, EMBO J. 3:1671-1680, 1984; Broglie *et al.*, Science 224:838-843, 1984) or heat shock promoters, *e.g.*, soybean hsp17.5-E or hsp17.3-B (Gurley *et al.*, Mol. Cell. Biol. 6:599-565, 1986) may be used. These constructs can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, microinjection, electroporation, etc. For reviews of such techniques see, *e.g.*, Weissbach & Weissbach, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp. 421-463, 1988; and Grierson & Corey, Plant Molecular Biology, 2nd Ed., Blackie, London, Ch. 7-9, 1988.

In one insect expression system that may be used to produce the peptides of the invention, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express the foreign genes. The virus grows in *Spodoptera frugiperda* cells. A coding sequence may be cloned into non-essential regions (for example the polyhedron gene) of the virus and placed under control of an AcNPV promoter (for example, the polyhedron promoter). Successful insertion of a coding sequence will result in inactivation of the polyhedron gene and production of non-occluded recombinant virus (*i.e.*, virus lacking the proteinaceous coat coded for by the polyhedron gene). These recombinant viruses are then

used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed. (e.g., see Smith *et al.*, J. Virol., 46:584, 1983; Smith, U.S. Patent No. 4,215,051). Further examples of this expression system may be found in Current Protocols in Molecular Biology, Vol. 2, Ausubel *et al.*, eds., Greene Publish. Assoc. & Wiley Interscience.

- 5 In mammalian host cells, a number of viral based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a coding sequence may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential
10 region of the viral genome (e.g. Region E1 or E3) will result in a recombinant virus that is viable and capable of expressing peptide in infected hosts. (e.g., See Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:3655-3659, 1984). Alternatively, the vaccinia 7.5 K promoter may be used, (see, e.g., Mackett *et al.*, Proc. Natl. Acad. Sci. USA, 79:7415-7419, 1982; Mackett *et al.*, J. Virol., 49:857-864, 1984; Panicali *et al.*, Proc. Natl. Acad. Sci. 79:4927-
15 4931, 1982).

Other expression systems for producing linear or non-cyclized forms of the cyclic peptides used in the invention will be apparent to those having skill in the art.

Purification of the Peptides and Peptide Analogues

- The peptides and peptide analogues used in the invention can be purified by art-known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography and the like. The actual conditions used to purify a particular peptide or analogue will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity, etc., and will be apparent to those having skill in the art.
20
For affinity chromatography purification, any antibody which specifically binds the peptides or peptide analogues may be used. For the production of antibodies, various host animals, including but not limited to rabbits, mice, rats, etc., may be immunized by injection with a linear or cyclic peptide. The peptide may be attached to a suitable carrier, such as BSA, by means of a side chain functional group or linkers attached to a side chain
25 functional group. Various adjuvants may be used to increase the immunological response,
30

depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacilli

5 5 **Calmette-Duerin) and *Corynebacterium parvum*.**

Monoclonal antibodies to a peptide may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein, *Nature*, 256:495-497, 1975; the human B-cell hybridoma technique,

- 10 **Kosbor et al.**, *Immunology Today*, 4:72, 1983; **Cote et al.**, *Proc. Natl. Acad. Sci., USA*, 80:2026-2030, 1983; and the EBV-hybridoma technique (**Cole et al.**, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (1985)). In addition, techniques developed for the production of "chimeric antibodies" (**Morrison et al.**, *Proc. Natl. Acad. Sci., USA*, 81: 6851-6855, 1984; **Neuberger et al.**, *Nature*, 312:604-608, 1984;
- 15 **Takada et al.**, *Nature*, 314:452-454, 1985) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce cyclic peptide-specific single chain antibodies.

- 20 Antibody fragments which contain deletions of specific binding sites may be generated by known techniques. For example, such fragments include but are not limited to $F(ab')_2$ fragments, which can be produced by pepsin digestion of the antibody molecule and Fab fragments, which can be generated by reducing the disulfide bridges of the $F(ab')_2$ fragments. Alternatively, Fab expression libraries may be constructed (**Huse et al.**, *Science* 246: 1275-1281, 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for the cyclic peptide of interest.

The antibody or antibody fragment specific for the desired cyclic peptide can be attached, for example, to agarose, and the antibody-agarose complex is used in immunochromatography to purify cyclic peptides of the invention. See, Scopes, Protein

- 30 Purification: Principles and Practice, Springer-Verlag New York, Inc., NY, 1984; Livingstone, Methods Enzymology: Immunoaffinity Chromatography of Proteins 34:723-

731, 1974.

Formulation and Route of Administration

The compounds of the invention, may be administered to a subject *per se* or in the form of a pharmaceutical composition. Pharmaceutical compositions comprising the
5 compounds of the invention may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiological acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active peptides or peptide
10 analogues into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For topical administration the compounds of the invention may be formulated as solutions, gels, ointments, creams, suspensions, *etc.* as are well-known in the art.

Systemic formulations include those designed for administration by injection, *e.g.*
15 subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration.

For injection, the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory
20 agents such as suspending, stabilizing and/or dispersing agents.

Alternatively, the compounds may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

25 For oral administration, the compounds can be readily formulated by combining the active peptides or peptide analogues with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. For oral solid formulations such as, for example,
30 powders, capsules and tablets, suitable excipients include fillers such as sugars, such as

lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium, carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP); granulating agents; and binding agents. If desired,

- 5 disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, atgar, or alginic acid or a salt thereof such as sodium alginate.

If desired, solid dosage forms may be sugar-coated or enteric-coated using standard techniques.

For oral preparations such as, for example, suspensions, elixirs and solutions,

- 10 suitable carriers, excipients or diluents include water, glycols, oils, alcohols, etc.

Additionally, flavoring agents, preservatives, coloring agents and the like may be added.

For buccal administration, the compounds may take the form of tablets, lozenges, etc. formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present

- 15 invention are conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or
20 insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

- 25 In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion
30 exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Alternatively, other pharmaceutical delivery systems may be employed. Liposomes and emulsions are well known examples of delivery vehicles that may be used to deliver peptides and peptide analogues of the invention. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity.

- 5 Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid polymers containing the therapeutic agent. Various of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and
- 10 the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

As the compounds of the invention may contain charged side chains or termini, they may be included in any of the above-described formulations as the free acids or bases or as pharmaceutically acceptable salts. Pharmaceutically acceptable salts are those salts

- 15 which substantially retain the antimicrobial activity of the free bases and which are prepared by reaction with inorganic acids. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms.

Effective Dosages

- The compounds of the invention will generally be used in an amount effective to
- 20 achieve the intended purpose. For use to treat or prevent osteoclastogenesis or osteoclast activity, the compounds of the invention, or pharmaceutical compositions thereof, are administered or applied in a therapeutically effective amount. By therapeutically effective amount is meant an amount which is effective to ameliorate, or prevent the symptoms of the disease or disorder, or prolong the survival of the patient being treated. Determination
 - 25 of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.

For systemic administration, a therapeutically effective dose can be estimated initially from *in vitro* assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC₅₀ as determined in cell

- 30 culture (*i.e.*, the concentration of test compound that inhibits 50% of TNF-R: TNF-binding

DOCUMENT EDITION 20190630

interactions). Such information can be used to more accurately determine useful doses in humans.

Initial dosages can also be estimated from *in vivo* data, e.g., animal models, using techniques that are well known in the art. One having ordinary skill in the art could readily

5 optimize administration to humans based on animal data.

Dosage amount and interval may be adjusted individually to provide plasma levels of the compounds which are sufficient to maintain therapeutic effect. Usual patient dosages for administration by injection range from about 0.1 to 5 mg/kg/day, preferably from about 0.5 to 1 mg/kg/day. Therapeutically effective serum levels may be achieved by

10 administering multiple doses each day.

In cases of local administration or selective uptake, the effective local concentration of the compounds may not be related to plasma concentration. One having skill in the art will be able to optimize therapeutically effective local dosages without undue experimentation.

15 The amount of compound administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

Toxicity

Preferably, a therapeutically effective dose of the compounds described herein will

20 provide therapeutic benefit without causing substantial toxicity.

Toxicity of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD₅₀ (the dose lethal to 50% of the population) or the LD₁₀₀ (the dose lethal to 100% of the population). The dose ratio between toxic and therapeutic effect is the therapeutic

25 index. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulation a dosage range that is not toxic for use in human. The dosage of the compounds described herein lies preferably within a range of circulating concentrations that include the effective dose with little or not toxicity. The dosage may vary within this range depending upon the

30 dosage form employed and the route of administration utilized. The exact formulation,

route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See, e.g., Fingl *et al.*, In: The Pharmacological Basis of Therapeutics, Ch.1, p.1, 1975).

The invention having been described, the following examples are offered by way of 5 illustration and not limitation.

EXAMPLES

Example 1

Recently, therapeutic peptidomimetics that interfere with the TNF/TNF receptor 10 interaction have been developed based on atomic structures deduced from the crystal structures of TNF- α and the TNF β /TNF receptor complex (Takasaki *et al.* Nature Biotechnology, 15:1266-1270, 1997). The most critical TNF- α recognition site was localized to the first loop of the third domain of TNF receptor (residues 107-114). A peptidomimetic (WP9QY) engineered to mimic this recognition site efficiently 15 antagonized the effects of TNF-binding to the TNF- α receptor in L929 lymphocytes.

WP9QY peptide was tested at concentrations ranging from about 5 μ M to about 500 μ M for its effect on osteoclast formation using the co-culture system induced by 1,250H2D3 (1alpha,25-dihydroxyvitamin D3) and PGE2. Osteoclastogenesis was dose- and time-dependently inhibited by the peptide WP9QY (IC_{50} = 250 μ M), but this IC_{50} was 20 50-fold higher than what was required for the TNF/TNF receptor interaction (5 μ M). This difference suggests that the WP9QY peptide inhibits osteoclastogenesis by interfering not with the TNF/TNF receptor interaction but with another related ligand-receptor pair such as TRANCE/RANK. This was confirmed by demonstrating that WP9QY inhibits TRANCE-induced marrow cultures. There was a reciprocal dose-dependence of WP9QY 25 and TRANCE. Thus, WP9QY is capable of interfering not only with the TNF/TNF receptor interaction but also with the RANK Ligand/RANK interaction, thereby decreasing the osteoclastogenic potential of this cytokine.

Example 2

Materials and Methods

30 Human recombinant TNF- α and 125 I-labeled TNF- α were obtained from Amersham

Life Science, Inc. (Arlington Heights, IL). TNF-R(I) or p55 extracellular domain-IgG heavy chain chimeric protein was prepared by expression of a cDNA construct (Peppel *et al.*, J. Exp. Med. 174:1483, 1991; Williams *et al.*, Immunol. 84:433, 1995). Anti-TNF- α monoclonal antibody was prepared according to Doring *et al.* (Molecular Immunol.

- 5 31:1059, 1994) and anti-TNF-R(I) monoclonal antibody (htr-9) was obtained from BMA Biomedicals AG (Augst, Switzerland).

Molecular Modeling

- Computer modeling was performed using Quanta 4.0 (Molecular Simulation Inc., MA). The model peptides were constructed from their sequences and folded using
- 10 CHARMM. The side chains of amino acid residues were first positioned to permitted conformation using Ponders rotamer (Ponder *et al.*, J. Mol. Biol. 193:775-791, 1987) database provided in QUANTA. Then, the folded peptides were minimized to convergence with the dielectric constant set to 80.
- The crystal structure of the TNF- β /TNF-R(I) complex (Banner *et al.*, Cell 73:431, 1993) was utilized to determine the binding sites of TNF-R for TNF- α . The first (residues 56-73) and second (residues 76-83) loops of domain 2 and the first loop (residues 107-114) of domain 3 of the TNF-R were explored for use in designing peptides. The essential amino acid sequences of TNF-R for binding interactions with TNF- α were identified as structural templates by superimposing TNF- α to TNF- β complexed with its cognate receptor. Then, 5-8 amino acid-long peptides derived from TNF-R as shown in Table 2 were used as templates for the design of exocyclic peptides. Additional peptides were derived from CDR sequences of a light chain of an anti-TNF- α neutralizing antibody, CDR1L of Di62 (Doring *et al.*, Mol. Immunol. 31:1059, 1994). Exocyclic modifications such as peptide cyclization and addition of aromatic amino acids such as Phe and Tyr to the ends of each peptide were performed as described (Zhang *et al.*, Nature Biotech. 14:472, 1996; Zhang *et al.*, Nature Biotech 15:150, 1997).

Peptide Synthesis, Cyclization and Purification

Linear peptides were synthesized by solid-phase methods, deprotected, and released from the resin utilizing standard methodology well known to those skilled in the

art. Peptides were precipitated and purified by high performance liquid chromatography (HPLC) utilizing a C18 column and then lyophilized. The purity of such peptides was greater than 95% as measured by HPLC analysis.

The peptides containing internal Cys residues were oxidized by dissolving them at

- 5 100 µg/ml in distilled water adjusted or buffered to pH 8.0 - 8.5, for example, by $(\text{NH}_4)_2\text{CO}_3$ with stirring and exposure to air at 4°C for <10 days until 95% formation of intramolecular disulfide bonds had been confirmed by DTNB (Sigma, St. Louis, MO) which determined free sulphydryls in peptides (Habeeb, Anal. Bioch. 56:60, 1973; Angeletti *et al.*, In Techniques in Protein Chemistry VII, Ed. Marsak, Academic Press, San
- 10 Diego, CA., pp. 81-91, 1996). Briefly, peptides (100 µg/ml, 50 µl) and DTNB (10mM, 50 µl) were added to 0.1 M sodium phosphate buffer (pH 8.0, 1 ml), incubated in the dark for 30 minutes, and the absorbance at 420 nm was determined and compared with the linear unoxidized peptides.

The cyclized peptides were lyophilized, purified by HPLC utilizing a C18

- 15 preparative column and a size exclusion column Protein-Pak 60 (Waters, Milford, MA). The purity of the peptides was shown to be greater than 95% by HPLC analysis. The concentration of each cyclized peptide was calculated based on UV intensity versus the corresponding linear peptide by HPLC analysis.

- 20 Amino acid sequences corresponding to three TNF- α -binding loops of TNF-R were used as templates for the synthesis of a number of peptides. Cys residues were included in the linear peptides to enable their cyclization. Their identity was verified by mass spectrometry. Various exocyclic peptides are listed in Table 2.

Table 2
 Amino Acid Sequences of TNF- α Binding Sites in TNF-R and Exocyclic Peptides
 Derived from These Sites.

	TNF- α Binding Sites in the Receptor	Name	Exocyclic Peptides*	S.I.D. #
5	Binding Site - 5 TNF- α 53E 82R 85VSY87 125Q 127E	WP5 WP5N WP5R	YC FTASENH CY YC FTNSENH CY YC FTRSENH CY	16 17 18
10	Receptor (loop 1 of domain 2) 60 FTASENH 66	WP5J WP5JY WP5JN WP5JR WP5VR	FC ASENH CY YC ASENH CY FC NSENH CY FC NSENR CY FC NSVENR CY	19 20 21 22 23
15		WP1** WP1R**	YC SQSVSND CF FC VSNDR CY	28 29
20	Binding site - 8 TNF- α 65K 67Q 113P 115Y 143L 145A	WP8L WP8JP WP8J WP8JF	YC RKELGQV CY YC KEPGQ CY YC RKEMG CY FC RKEMG CY	24 25 26 27
25	Binding site - 9 TNF- α 72THVL75 77T 97I 137 N	WP9Q WP9ELY WP9Y WP9QY	YC WSQNL CY YC CELSQYL CY YC WSQNY CY YC WSQYL CY	13 12 14 15
30	Receptor (loop 1 of domain 3) 107 WSENL 111			

* Peptides were cyclized with cysteine disulfide bridges

35 ** WP1 and WP1R were derived from an anti-TNF- α antibody (Di62, CDR1L) and the template sequence is QSVSNDV.

Example 3

Identification of Osteoclasts Formed *in Vitro*

TRAP refers to tartrate resistant acid phosphatase which identifies osteoclast-like cells. Osteoprotegerin (OPG) is a naturally occurring secreted protein with homology to members of the TNF receptor family. Administration of OPG *in vivo* inhibits osteoclastogenesis and associated bone resorption and blocks the pathological increase in

osteoclast numbers and activity seen in animal models that mimic osteopenic disorders in humans. OPG can be used as a positive control in the TRAP assay.

- Cytochemical staining for TRAP is widely used for identifying osteoclasts *in vivo* and *in vitro*. Naphthol AS-MX phosphate 5 mg. Sigma, St. Louis, MO) is resolved in 0.5 ml of N, N-dimethylformamide (Wako). Thirty milligrams of fast red violet LB salt (Sigma) and 50 ml of 0.1 M sodium acetate buffer (pH 5.0) containing 50 mM sodium tartrate are added to the mixture (the TRAP-staining solution). Cells are fixed with 3.7% (v/v) formaldehyde in Ca²⁺- and Mg²⁺-free phosphate-buffered saline [PBS(-)] for 10 min. fixed again with ethanol-acetone (50:50, v:v) for 1 min. and incubated with the TRAP-staining solution for 10 min. at room temperature. TRAP-positive osteoclasts appear as red cells. The incubation period longer than 10 min. should be avoided since cells other than osteoclasts become weakly positive with time. After staining, cells are washed with distilled water, and TRAP-positive multinucleated cells having three or more nuclei are counted as osteoclasts under a microscope. (G.C. Nicholson, J.M. Mosely, P.M. Sexton, F.A.O. Mendelssohn, and T.J. Martin, *J. Clin. Invest.* 78, 355, 1986, which is incorporated herein by reference).


- The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention and any sequences which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications cited herein are incorporated by reference in their entirety.

CLAIMS

1. A method of inhibiting osteoclastogenesis comprising the step of administering to a patient an amount of an inhibitor effective to inhibit osteoclastogenesis.
2. The method of claim 1 wherein the inhibitor has the formula:

5



(I)


wherein:

- AC is a peptide of 3-18 amino acid residues which corresponds in primary sequence to a binding loop of a TNF-R superfamily member, and which may optionally contain one or more amino acid substitutions, or an analogue thereof wherein at least one amide linkage is replaced with a substituted amide or an isostere of amide;
- 10 AB₁ is a moiety having a first functional group capable of forming a covalent linkage with one terminus of AC, a second functional group capable of forming a covalent linkage with AB₂ and a third functional group capable of forming a covalent linkage with AA₁ ;
- 15 AB₂ is a moiety having a first functional group capable of forming a covalent linkage with the second terminus of AC, a second functional group capable of forming a covalent linkage with AB₁ and a third functional group capable of forming a covalent linkage with AA₂;
- AA₁ is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB₂;
- 20 AA₂ is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB₂;

“=” is a covalent linkage; and

“≡” is a covalent linkage.

3. The method of Claim 2 in which the amino acid substitutions are conservative.
4. The method of Claim 3 in which the member of TNF-R superfamily is TNF-R p55.
5. The method of Claim 4 wherein the inhibitor has the formula:



wherein:

- B₁ and B₁₀ are each independently a peptide of 1-6 amino acids at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;
- 10 Z₂ is a moiety that is capable of forming a covalent linkage with B₁, X₃ and Z₉;
- Z₉ is a moiety that is capable of forming a covalent linkage with B₁₀, X₈ and Z₂;
- X₃ is absent or a hydrophilic amino acid;
- X₄ is a hydrophobic amino acid;
- X₅ is a hydrophobic amino acid;
- 15 X₆ is a hydrophobic amino acid;
- X₇ is a hydrophobic or hydrophilic amino acid;
- X₈ is a hydrophobic or hydrophilic amino acid;
- “-“ is an amide, substituted amide or an isostere of amide thereof;
- “=“ is a covalent linkage; and
- 20 “≡“ is a covalent linkage.

6. The method of Claim 5, wherein:

B₁ and B₁₀ are each independently a peptide of 1-2 amino acids, at least one of which is an aromatic amino acid;

Z₂ and Z₉ are each independently a Cys-like amino acid;

5 X₃ is absent or an acidic amino acid;

X₄ is an aromatic or apolar amino acid;

X₅ is a polar amino acid;

X₆ is a polar amino acid;

X₇ is an aromatic or polar amino acid;

10 X₈ is an aromatic, apolar or polar amino acid;

“-” is an amide linkage;

“=” is a disulfide linkage; and

“≡” is an amide linkage.

6. The method of Claim 5, wherein:

15 B₁ and B₁₀ are each independently Tyr or Phe;

Z₂ and Z₉ are each Cys;

X₃ is absent or Glu;

X₄ is Trp or Leu;

X₅ is Ser;

20 X₆ is Gln;

X₇ is Tyr or Asn;

X₈ is Tyr or Leu;


“-” is an amide linkage;

“=” is a disulfide linkage; and

25 “≡” is an amide linkage.

8. The method of Claim 7, wherein said inhibitor is selected from the group consisting of WP9Q - SEQ ID NO:13, WP9ELY - SEQ ID NO:12, WP9Y - SEQ ID NO:14, and WP9QY - SEQ ID NO:15.

9. The method of Claim 4, wherein the inhibitor has the formula:



wherein:

B_{11} and B_{22} are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

- 5 Z_{12} is a moiety that is capable of forming a covalent linkage with B_{11} , X_{13} and Z_{21} ;
- Z_{21} is a moiety that is capable of forming a covalent linkage with B_{22} , X_{20} and Z_{12} ;
- X_{13} is absent or hydrophobic amino acid;
- X_{14} is absent or hydrophilic amino acid;
- X_{15} is a hydrophilic or hydrophobic amino acid;
- 10 X_{16} is a hydrophilic amino acid;
- X_{17} is absent or a hydrophobic amino acid;
- X_{18} is a hydrophilic amino acid;
- X_{19} is a hydrophilic amino acid;
- X_{20} is a hydrophilic amino acid;
- 15 “-“ is an amide, a substituted amide or an isostere of amide thereof;
- “=“ is a covalent linkage; and
- “≡“ is a covalent linkage.

10. The method of Claim 9, wherein:

- B_{11} and B_{22} are each independently a peptide of 1-3 amino acids, at least one of which is an aromatic amino acid;


- Z₁₂ and Z₂₁ are each independently a Cys-like amino acid;
X₁₃ is absent or an aromatic amino acid;
X₁₄ is absent or a polar amino acid;
X₁₅ is a basic, polar or apolar amino acid;
5 X₁₆ is a polar amino acid;
X₁₇ is absent or an apolar amino acid;
X₁₈ is an acidic amino acid;
X₁₉ is a polar amino acid;
X₂₀ is a basic amino acid;
10 “-“ is an amide linkage;
“=“ is a disulfide linkage; and
“≡“ is an amide linkage.

- 11.** The method of Claim 10, wherein:
B₁₁ and B₂₂ are each independently Tyr or Phe;
15 Z₁₂ and Z₂₁ are each Cys;
X₁₃ is absent or Phe;
X₁₄ is absent or Thr;
X₁₅ is Ala, Asn or Arg;
X₁₆ is Ser;
20 X₁₇ is absent or Val;
X₁₈ is Glu;
X₁₉ is Asn;
X₂₀ is Arg or His;
“-“ is an amide linkage;
25 “=“ is a disulfide linkage; and
“≡“ is an amide linkage.

- 12.** The method of Claim 11, wherein said inhibitor is selected from the group consisting of WP5 - SEQ ID NO:16, WP5N - SEQ ID NO:17, WP5R - SEQ ID NO:18, WP5J - SEQ ID NO:19, WP5JY - SEQ ID NO:20, WP5JN - SEQ ID NO:21, WP5JR -

SEQ ID NO:22, and WP5VR - SEQ ID NO:23.

13. The method of Claim 4, wherein the inhibitor has the formula:



wherein:

- 5 B_{23} and B_{33} are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;
-
- Z_{24} is a moiety that is capable of forming a covalent linkage with B_{23} , X_{25} and Z_{32} ;
- Z_{32} is a moiety that is capable of forming a covalent linkage with B_{33} , X_{31} and Z_{24} ;
- X_{25} is absent or a hydrophilic amino acid;
- 10 X_{26} is a hydrophilic amino acid;
- X_{27} is a hydrophilic amino acid;
- X_{28} is a hydrophilic amino acid;
- X_{29} is a hydrophilic amino acid;
- X_{30} is absent or a hydrophilic amino acid;
- 15 X_{31} is absent or a hydrophilic amino acid;
- “-“ is an amide, a substituted amide or an isostere of amide;
- “=“ is a covalent linkage; and
- “≡“ is a covalent linkage.

14. The method of Claim 13, wherein:

- 20 B_{23} and B_{33} are each independently a peptide of 1-3 amino acids, at least one of

which is an aromatic amino acid;

Z_{24} and Z_{32} are each independently a Cys-like amino acid;

X_{25} is absent or a basic amino acid;

X_{26} is a basic amino acid;

5 X_{27} is an acidic amino acid;

X_{28} is an apolar amino acid;

X_{29} is an apolar amino acid;

X_{30} is absent or a polar amino acid;

X_{31} is absent or an apolar amino acid;

10 “-“ is an amide linkage’

“=” is a disulfide linkage; and

“≡” is an amide linkage.

15. The method of Claim 14, wherein:

B_{23} and B_{33} are each independently Tyr or Phe;

15 Z_{24} and Z_{32} are each Cys;

X_{25} is absent or Arg;

X_{26} is Lys;

X_{27} is Glu;

X_{28} is leu, Pro or Met;

20 X_{29} is Gly;

X_{30} is absent or Gln;

X_{31} is absent or Val;

“-“ is an amide linkage;

“=” is a disulfide linkage; and


25 “≡” is an amide linkage.

16. The method of Claim 15, wherein said inhibitor is selected from the group consisting of WP8L - SEQ ID NO:24, WP8JP - SEQ ID NO:25, WP8J - SEQ ID NO:26, and WP8JF - SEQ ID NO:27.

17. A method of treating patients who have diseases characterized by bone loss comprising the step of administering to said patient an amount of an inhibitor effective to inhibit such bone loss.

18. The method of claim 17 wherein said inhibitor is a compound having the formula:

5



wherein:

AC is a peptide of 3-18 amino acid residues which corresponds in primary sequence to a binding loop of a TNF-R superfamily member, and which may optionally contain one or more amino acid substitutions, or an analogue thereof wherein at least one amide linkage is replaced with a substituted amide or an isostere of amide;

AB₁ is a moiety having a first functional group capable of forming a covalent linkage with one terminus of AC, a second functional group capable of forming a covalent linkage with AB₂, and a third functional group capable of forming a covalent linkage with AA₁;

15 AB₂ is a moiety having a first functional group capable of forming a covalent linkage with the second terminus of AC, a second functional group capable of forming a covalent linkage with AB₁ and a third functional group capable of forming a covalent linkage with AA₂;


AA₁ is a moiety having hydrophobic properties and a functional group capable of 20 forming a covalent linkage with the third functional group of AB₁;

AA₂ is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB₂;

“=” is a covalent linkage; and

“≡” is a covalent linkage.

19. The method of claim 18 wherein the inhibitor has the formula:



wherein:

- B_1 and B_{10} are each independently a peptide of 1-6 amino acids, at least one of
- 5 which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;
- Z_2 is a moiety that is capable of forming a covalent linkage with B_1 , X_3 and Z_9 ;
- Z_9 is a moiety that is capable of forming a covalent linkage with B_{10} , X_8 and Z_2 ;
- X_3 is absent or a hydrophilic amino acid;
- X_4 is a hydrophobic amino acid;
- 10 X_5 is a hydrophilic amino acid;
- X_6 is a hydrophilic amino acid;
- X_7 is a hydrophobic or hydrophilic amino acid;
- X_8 is a hydrophobic or hydrophilic amino acid;
- “-” is an amide, substituted amide or an isostere of amide thereof;
- 15 “=” is a covalent linkage; and
- “≡” is a covalent linkage.

20. The method of claim 19 wherein:

- B_1 and B_{10} are each independently a peptide of 1-3 amino acids, at least one of which is an aromatic amino acid;
- 20 Z_2 and Z_9 are each independently a Cys-like amino acid;
- X_3 is absent or an acidic amino acid;
- X_4 is an aromatic or apolar amino acid;
- X_5 is a polar amino acid;

X₆ is a polar amino acid;
X₇ is an aromatic or polar amino acid;
X₈ is an aromatic, apolar or polar amino acid;
“-“ is an amide linkage;
5 “=“ is a disulfide linkage; and
“≡“ is an amide linkage.

21. The method of claim 20 wherein:

B₁ and B₁₀ are each independently Tyr or Phe;
Z₂ and Z₉ are each Cys;

10 X₃ is absent or Glu;

X₄ is Trp or Leu;

X₅ is Ser;

X₆ is Gln;

X₇ is Tyr or Asn;

15 X₈ is Tyr or Leu;

“-“ is an amide linkage;


“=“ is a disulfide linkage; and

“≡“ is an amide linkage.

22. The method of claim 18 wherein the compound is selected from the group

20 consisting of WP9Q - SEQ ID NO: 13, WP9ELY - SEQ ID NO: 12, WP9Y - SEQ ID NO: 14, and WP9QY - SEQ ID NO: 15.

23. The method of claim 18 wherein the inhibitor has the formula:



wherein:

B_{11} and B_{22} are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

- 5 Z_{12} is a moiety that is capable of forming a covalent linkage with B_{11} , X_{13} and Z_{21} ;
- Z_{21} is a moiety that is capable of forming a covalent linkage with B_{22} , X_{20} and Z_{12} ;
- X_{13} is absent or hydrophobic amino acid;
- X_{14} is absent or a hydrophilic amino acid;
- X_{15} is a hydrophilic or hydrophobic amino acid;
- 10 X_{16} is a hydrophilic amino acid;
- X_{17} is absent or a hydrophobic amino acid;
- X_{18} is a hydrophilic amino acid;
- X_{19} is a hydrophilic amino acid;
- X_{20} is a hydrophilic amino acid;
- 15 “-” is an amide, a substituted amide or an isostere of amide thereof;
- “=” is a covalent linkage; and
- “≡” is a covalent linkage.


24. The method of claim 23 wherein:

- B_{11} and B_{22} are each independently a peptide of 1-3 amino acids, at least one of
20 which is an aromatic amino acid;

- Z₁₂ and Z₂₁ are each independently a Cys-like amino acid;
X₁₃ is absent or an aromatic amino acid;
X₁₄ is absent or a polar amino acid;
X₁₅ is a basic, polar or apolar amino acid;
- 5 X₁₆ is a polar amino acid;
X₁₇ is absent or an apolar amino acid;
X₁₈ is an acidic amino acid;
X₁₉ is a polar amino acid;
X₂₀ is a basic amino acid;
- 10 “-“ is an amide linkage;
“=“ is a disulfide linkage; and
“≡“ is an amide linkage.
25. The method of claim 24 wherein:
B₁₁ and B₂₂ are each independently Tyr or Phe;
- 15 Z₁₂ and Z₂₁ are each Cys;
X₁₃ is absent or Phe;
X₁₄ is absent or Thr;
X₁₅ is Ala, Asn or Arg;
X₁₆ is Ser;
- 20 X₁₇ is absent or Val;
X₁₈ is Glu;
X₁₉ is Asn;
X₂₀ is Arg or His;
“-“ is an amide linkage;
- 25 “=“ is a disulfide linkage; and
“≡“ is an amide linkage.
26. The method of claim 25 wherein the inhibitor is selected from the group consisting of WP5 - SEQ ID NO: 16, WP5N - SEQ ID NO: 17, WP5R - SEQ ID NO: 18, WP5J - SEQ ID NO: 19, WP5JY - SEQ ID NO: 20, WP5JN - SEQ ID NO: 21, WP5JR - SEQ ID

NO: 22, and WP5VR - SEQ ID NO: 23.

27. The method of claim 18 wherein the inhibitor has the formula:



wherein:

- 5 B_{23} and B_{33} are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;
- Z_{24} is a moiety that is capable of forming a covalent linkage with B_{23} , X_{25} and Z_{32} ;
- Z_{32} is a moiety that is capable of forming a covalent linkage with B_{33} , X_{31} and Z_{24} ;
- X_{25} is absent or a hydrophilic amino acid;
- 10 X_{26} is a hydrophilic amino acid;
- X_{27} is a hydrophilic amino acid;
- X_{28} is a hydrophobic amino acid;
- X_{29} is a hydrophobic amino acid;
- X_{30} is absent or a hydrophobic amino acid;
- 15 X_{31} is absent or a hydrophobic amino acid;
- “-“ is an amide, a substituted amide or an isostere of amide;
- “=“ is a covalent linkage; and
- “≡“ is a covalent linkage.

28. The method of claim 27 wherein:

- 20 B_{23} and B_{33} are each independently a peptide of 1-3 amino acids, at least one of

which is an aromatic amino acid;

Z_{24} and Z_{32} are each independently a Cys-like amino acid;

X_{25} is absent or a basic amino acid;

X_{26} is a basic amino acid;

5 X_{27} is an acidic amino acid'

X_{28} is an apolar amino acid;

X_{29} is an apolar amino acid;

X_{30} is absent or a polar amino acid;

X_{31} is absent or an apolar amino acid;

10 “-“ is an amide linkage;

“=“ is a disulfide linkage; and

“≡“ is an amide linkage.

29. The method of claim 28 wherein:

B_{23} and B_{33} are each independently Tyr or Phe;

15 Z_{24} and Z_{32} are each Cys;

X_{25} is absent or Arg;

X_{26} is Lys;

X_{27} is Glu;

X_{28} is Leu, Pro or Met;

20 X_{29} is Gly;

X_{30} is absent or Gln;

X_{31} is absent or Val;

“-“ is an amide linkage;

“=“ is a disulfide linkage; and

25 “≡“ is an amide linkage.

30. The method of claim 29 wherein the inhibitor is selected from the group consisting of WP8L - SEQ ID NO:24.


31. The method of claim 17 wherein the disease characterized by bone loss is selected

from the group consisting of osteoporosis, Paget's disease, metastatic bone disease, rheumatoid arthritis, and periodontal disease.

32. The method of claim 31 wherein the disease characterized by bone loss is osteoporosis.

5 33. A method of inhibiting bone resorption, comprising the step of administering to a patient an amount of an inhibitor effective to inhibit bone resorption.

34. The method of claim 33 wherein said inhibitor has the formula:



(I)

wherein:

10 AC is a peptide of 3-18 amino acid residues which corresponds in primary sequence to a binding loop of a TNF-R superfamily member, and which may optionally contain one or more amino acid substitutions, or an analogue thereof wherein at least one amide linkage is replaced with a substituted amide or an isostere of amide;

15 AB₁ is a moiety having a first functional group capable of forming a covalent linkage with one terminus of AC, a second functional group capable of forming a covalent linkage with AB₂ and a third functional group capable of forming a covalent linkage with AA₁;

20 AB₂ is a moiety having a first functional group capable of forming a covalent linkage with the second terminus of AC, a second functional group capable of forming a covalent linkage with AB₁ and a third functional group capable of forming a covalent linkage with AA₂;

AA₁ is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB₂;

AA₂ is a moiety having hydrophobic properties and a functional group capable of forming a covalent linkage with the third functional group of AB₂;


5 “=” is a covalent linkage; and

“≡” is a covalent linkage.

35. The method of Claim 34 in which the amino acid substitutions are conservative.

36. The method of Claim 35 in which the member of TNF-R superfamily is TNF-R
p55.

10 37. The method of Claim 36 wherein the inhibitor has the formula:



wherein:

B₁ and B₁₀ are each independently a peptide of 1-6 amino acids at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

15 Z₂ is a moiety that is capable of forming a covalent linkage with B₁, X₃ and Z₉;

Z₉ is a moiety that is capable of forming a covalent linkage with B₁₀, X₈ and Z₂;

X₃ is absent or a hydrophilic amino acid;

X₄ is a hydrophobic amino acid;

X₅ is a hydrophobic amino acid;

20 X₆ is a hydrophobic amino acid;

X₇ is a hydrophobic or hydrophilic amino acid;

X₈ is a hydrophobic or hydrophilic amino acid;

"-" is an amide, substituted amide or an isostere of amide thereof;

"=" is a covalent linkage; and

"≡" is a covalent linkage.

5 38. The method of Claim 37, wherein:

B₁ and B₁₀ are each independently a peptide of 1-2 amino acids, at least one of which is an aromatic amino acid;

Z₂ and Z₉ are each independently a Cys-like amino acid;

X₃ is absent or an acidic amino acid;

10 X₄ is an aromatic or apolar amino acid;

X₅ is a polar amino acid;

X₆ is a polar amino acid;

X₇ is an aromatic or polar amino acid;

X₈ is an aromatic, apolar or polar amino acid;

15 "-" is an amide linkage;

"=" is a disulfide linkage; and

"≡" is an amide linkage.

39. The method of Claim 38, wherein:

B₁ and B₁₀ are each independently Tyr or Phe;

20 Z₂ and Z₉ are each Cys;

X₃ is absent or Glu;

X₄ is Trp or Leu;

X₅ is Ser;

X₆ is Gln;

25 X₇ is Tyr or Asn;

X₈ is Tyr or Leu;

"-" is an amide linkage;


"=" is a disulfide linkage; and

"≡" is an amide linkage.

40. The method of Claim 39, wherein said inhibitor is selected from the group consisting of WP9Q - SEQ ID NO:13, WP9ELY - SEQ ID NO:12, WP9Y - SEQ ID NO:14, and WP9QY - SEQ ID NO:15.

41. The method of Claim 36, wherein the inhibitor has the formula:

5



wherein:

B₁₁ and B₂₂ are each independently a peptide of 1-6 amino acids, at least one of which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;

- Z₁₂ is a moiety that is capable of forming a covalent linkage with B₁₁, X₁₃ and Z₂₁;
- 10 Z₂₁ is a moiety that is capable of forming a covalent linkage with B₂₂, X₂₀ and Z₁₂;
- X₁₃ is absent or hydrophobic amino acid;
- X₁₄ is absent or hydrophilic amino acid;
- X₁₅ is a hydrophilic or hydrophobic amino acid;
- X₁₆ is a hydrophilic amino acid;
- 15 X₁₇ is absent or a hydrophobic amino acid;
- X₁₈ is a hydrophilic amino acid;
- X₁₉ is a hydrophilic amino acid;
- X₂₀ is a hydrophilic amino acid;
- “-” is an amide, a substituted amide or an isostere of amide thereof;
- 20 “=” is a covalent linkage; and

“ \equiv ” is a covalent linkage.

42. The method of Claim 41, wherein:

B₁₁ and B₂₂ are each independently a peptide of 1-3 amino acids, at least one of which is an aromatic amino acid;

5 Z₁₂ and Z₂₁ are each independently a Cys-like amino acid;

X₁₃ is absent or an aromatic amino acid;

X₁₄ is absent or a polar amino acid;

X₁₅ is a basic, polar or apolar amino acid;

X₁₆ is a polar amino acid;

10 X₁₇ is absent or an apolar amino acid;

X₁₈ is an acidic amino acid;

X₁₉ is a polar amino acid;

X₂₀ is a basic amino acid;

“-“ is an amide linkage;

15 “=“ is a disulfide linkage; and

“ \equiv ” is an amide linkage.

43. The method of Claim 42, wherein:

B₁₁ and B₂₂ are each independently Tyr or Phe;

Z₁₂ and Z₂₁ are each Cys;

20 X₁₃ is absent or Phe;

X₁₄ is absent or Thr;

X₁₅ is Ala, Asn or Arg;

X₁₆ is Ser;

X₁₇ is absent or Val;

25 X₁₈ is Glu;

X₁₉ is Asn;

X₂₀ is Arg or His;


“-“ is an amide linkage;

“=“ is a disulfide linkage; and

“≡” is an amide linkage.

44. The method of Claim 43, wherein said inhibitor is selected from the group consisting of WP5 - SEQ ID NO:16, WP5N - SEQ ID NO:17, WP5R - SEQ ID NO:18, WP5J - SEQ ID NO:19, WP5JY - SEQ ID NO:20, WP5JN - SEQ ID NO:21, WP5JR - 5 SEQ ID NO:22, and WP5VR - SEQ ID NO:23.

45. The method of Claim 36, wherein the inhibitor has the formula:



wherein:

- B₂₃ and B₃₃ are each independently a peptide of 1-6 amino acids, at least one of
10 which is a hydrophobic amino acid, an aromatic moiety or a heteroaromatic moiety;
Z₂₄ is a moiety that is capable of forming a covalent linkage with B₂₃, X₂₅ and Z₃₂;
Z₃₂ is a moiety that is capable of forming a covalent linkage with B₃₃, X₃₁ and Z₂₄;
X₂₅ is absent or a hydrophilic amino acid;
X₂₆ is a hydrophilic amino acid;
15 X₂₇ is a hydrophilic amino acid;
X₂₈ is a hydrophilic amino acid;
X₂₉ is a hydrophilic amino acid;
X₃₀ is absent or a hydrophilic amino acid;
X₃₁ is absent or a hydrophilic amino acid;
20 “-“ is an amide, a substituted amide or an isostere of amide;

“=” is a covalent linkage; and

“≡” is a covalent linkage.

46. The method of Claim 45, wherein:

B_{23} and B_{33} are each independently a peptide of 1-3 amino acids, at least one of

5 which is an aromatic amino acid;

Z_{24} and Z_{32} are each independently a Cys-like amino acid;

X_{25} is absent or a basic amino acid;

X_{26} is a basic amino acid;

X_{27} is an acidic amino acid;

10 X_{28} is an apolar amino acid;

X_{29} is an apolar amino acid;

X_{30} is absent or a polar amino acid;

X_{31} is absent or an apolar amino acid;

“-“ is an amide linkage’

15 “=” is a disulfide linkage; and

“≡” is an amide linkage.

47. The method of Claim 46, wherein:

B_{23} and B_{33} are each independently Tyr or Phe;

Z_{24} and Z_{32} are each Cys;

20 X_{25} is absent or Arg;

X_{26} is Lys;

X_{27} is Glu;

X_{28} is leu, Pro or Met;

X_{29} is Gly;

25 X_{30} is absent or Gln;

X_{31} is absent or Val;

“-“ is an amide linkage;

“=” is a disulfide linkage; and

“≡” is an amide linkage.

48. The method of Claim 47, wherein said inhibitor is selected from the group consisting of WP8L - SEQ ID NO:24, WP8JP - SEQ ID NO:25, WP8J - SEQ ID NO:26, and WP8JF - SEQ ID NO:27.

ABSTRACT

Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. The present invention also provides peptides and peptide analogues designed from a binding loop of a member of the tumor necrosis factor receptor (TNF-R) superfamily. According to the methods, an amount of an inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of an inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.

Figure 1

TNF-R p55 TNF-R p75 TNF-R-<i>IP</i> NGF-R p75 CD27 CD30 (proximal) CD30 (distal) CD40 Fas OX40 4-IBB	70 80 90 100 110 120 130 140	DCRECESGSFTASENHLRHCLSCSK. . CRKEMGQVEISS CTVDRDTV CGCRKQNQYRHYSNLFQ. C FN CSLC LNG. . . . T VCDSCEDSTYTQLWNWWVPECLSGSRC SSDQVE. . . . TQA CTREQNRI CTCRPGWYCALSKQEGCRL C AP LRKC RPGFGV A VCATCAENSYNEHNNYL. . . TICQLCRP CDPVMGLEEIAPIAP CTSKRKQTQ CRCQPGMFCAAWALE. CTH C EL LSDC PPGTEAE E .CEPCLDSVTFSDDVVVSATEPCPKCTEC VGLQSMSAP . . . QCDPCIPGVSFSC..PDHHHTPHCESC RH CNSGLLVRN. CRKQCEPDYVLDEADRCTACVTSRD. DLVEKTP CAWNSSRV CECRPGMFCSTSAVNScar C FFHSVC PAGMIV K CRKQCEPDYVLDEAGRCTACVSCSRD. DLVEKTP CAWNSSRT CECRPGMICATSATNSCAR C VP YPIC AAETVT K ECLPCGESEFELDTWNR. . . ETHCHQHKY CDPNLGLRQQK GTSETDTI [CTCEEGWHCT...SEACES C VLHRSC SPGFGV K DCVPCQEGKEYTDKAHF. SSK.. [CRR.CRPC.GPGFYNDVVS. . KPCKPCTWC . NLRSGSERKQL CTTATQDTV CR.CSPCPPNSF. SSAGGQRTCDIC RQCKGVFRTRKE CSSTSNAE CDCTPPGFH. MC EQDCCKQQQEL T
---	---	--

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Mark I. Greene, Ramachandran Murali, Kazuhiro Aoki, William Carle Horne and Roland Baron

Group Art Unit: Not yet assigned

For: METHODS OF INHIBITING
OSTEOCLASTOGENESIS

Examiner: Not yet assigned

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a

Utility Patent Design Patent

is sought on the invention, whose title appears above, the specification of which:

- is attached hereto.
- was filed on _____ as Serial No. _____
- said application having been amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a-d) of any **foreign application(s)** for patent or inventor's certificate listed below and have also identified below

any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Priority Claimed (If X'd)	Country	Serial Number	Date Filed
<input type="checkbox"/>	_____	_____	_____
<input type="checkbox"/>	_____	_____	_____
<input type="checkbox"/>	_____	_____	_____
<input type="checkbox"/>	_____	_____	_____

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Date Filed	Patented/Pending/Abandoned
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional

Docket No. UPN-3832

application(s) listed below:

Serial Number	Date Filed
<u>60/146,090</u>	<u>July 28, 1999</u>

I hereby appoint the following persons of the firm of **WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP**, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania 19103 as attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

<u>Mark DeLuca</u>	<u>Reg. No. 33,229</u>
<u>Gwilym J. O. Attwell</u>	<u>Reg. No. 45,449</u>

Address all telephone calls and correspondence to:

Gwilym J. O. Attwell
WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone No.: **(215) 568-3100**
Facsimile No.: **(215) 568-3439**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: Mark I. Greene	Signature
Mailing Address: 300 Righters Mill Road Penn Valley Pennsylvania 19072	Date of Signature: _____
City/State of Actual Residence: Penn Valley, Pennsylvania	Citizenship: _____ United States

Name: Ramachandran Murali	Signature
Mailing Address: 41-6 Revere Road Drexel Hill, Pennsylvania 19026	Date of Signature: _____
City/State of Actual Residence: Drexel Hill, Pennsylvania 19026	Citizenship: _____ India

Name: Kazuhiro Aoki	Signature
Mailing Address: 3-10-10-807 Izumi-cho Narashino-shi Chiba 275-0006 JAPAN	Date of Signature: _____
City/State of Actual Residence: Chiba 275-0006 JAPAN	Citizenship: _____ Japanese

Name: William Carle Horne	<hr/>
Mailing Address: 246 Pleasant Point Road Branford, CT 06405	Signature
City/State of Actual Residence: Branford, CT	Date of Signature: _____
	Citizenship: <u>United States</u>

Name: Roland Baron	
Mailing Address: 9 Little Harbor Road Guilford, CT 06437	Signature Date of Signature: _____
City/State of Actual Residence: Guilford, CT 06437	Citizenship: <u>United States</u>

Name:	
Mailing Address:	Signature _____
City/State of Actual Residence:	Date of Signature: _____
	Citizenship: _____

SEQUENCE LISTING

<110> Greene, Mark
Murali, Ramachandran
Aoki, Kazuhiro
Baron, Roland

<120> Methods of Inhibiting Osteoclastogenesis

<130> UPN3832

<140>
<141>

<150> 60/146,090

<151> 1999-07-28

<160> 29

<170> PatentIn Ver. 2.1

<210> 1

<211> 74

<212> PRT

<213> Homo sapiens

<400> 1

Asp Cys Arg Glu Cys Glu Ser Gly Ser Phe Thr Ala Ser Glu Asn His
1 5 10 15

Leu Arg His Cys Leu Ser Cys Ser Lys Cys Arg Lys Glu Met Gly Gln
20 25 30

Val Glu Ile Ser Ser Cys Thr Val Asp Arg Asp Thr Val Cys Gly Cys
35 40 45

Arg Lys Asn Gln Tyr Arg His Tyr Trp Ser Glu Asn Leu Phe Gln Cys
50 55 60

Phe Asn Cys Ser Leu Cys Leu Asn Gly Thr
65 70

<210> 2

<211> 77

<212> PRT

<213> Homo sapiens

<400> 2
Val Cys Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu Trp Asn Trp
1 5 10 15

Val Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser Asp Gln Val
20 25 30

Glu Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys Thr Cys Arg
35 40 45

Pro Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys Arg Leu Cys
50 55 60

Ala Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala
65 70 75

<210> 3
<211> 77
<212> PRT
<213> Homo sapiens

<400> 3
Val Cys Ala Thr Cys Ala Glu Asn Ser Tyr Asn Glu His Trp Asn Tyr
1 5 10 15

Leu Thr Ile Cys Gln Leu Cys Arg Pro Cys Asp Pro Val Met Gly Leu
20 25 30

Glu Glu Ile Ala Pro Cys Thr Ser Lys Arg Lys Thr Gln Cys Arg Cys
35 40 45

Gln Pro Gly Met Phe Cys Ala Ala Trp Ala Leu Glu Cys Thr His Cys
50 55 60

Glu Leu Leu Ser Asp Cys Pro Pro Gly Thr Glu Ala Glu
65 70 75

<210> 4
<211> 76
<212> PRT
<213> Homo sapiens

<400> 4
Cys Glu Pro Cys Leu Asp Ser Val Thr Phe Ser Asp Val Val Ser Ala
1 5 10 15

Thr Glu Pro Cys Lys Pro Cys Thr Glu Cys Val Gly Leu Gln Ser Met
20 25 30

Ser Ala Pro Cys Val Glu Ala Asp Asp Ala Val Cys Arg Cys Ala Tyr
35 40 45

Gly Tyr Tyr Gln Asp Glu Thr Thr Gly Arg Cys Glu Ala Cys Arg Val
50 55 60

Cys Glu Ala Gly Ser Gly Leu Val Phe Ser Cys Gln
65 70 75

<210> 5

<211> 53

<212> PRT

<213> Homo sapiens

<400> 5

Gln Cys Asp Pro Cys Ile Pro Gly Val Ser Phe Ser Pro Asp His His
1 5 10 15

Thr Arg Pro His Cys Glu Ser Cys Arg His Cys Asn Ser Gly Leu Leu
20 25 30

Val Arg Asn Cys Thr Ile Thr Ala Asn Ala Glu Cys Ala Cys Arg Asn
35 40 45

Gly Trp Gln Cys Arg

50

<210> 6

<211> 74

<212> PRT

<213> Homo sapiens

<400> 6

Cys Arg Lys Gln Cys Glu Pro Asp Tyr Tyr Leu Asp Glu Ala Asp Arg
1 5 10 15

Cys Thr Ala Cys Val Thr Cys Ser Arg Asp Asp Leu Val Glu Lys Thr
20 25 30

Pro Cys Ala Trp Asn Ser Ser Arg Val Cys Glu Cys Arg Pro Gly Met
35 40 45

Phe Cys Ser Thr Ser Ala Val Asn Ser Cys Ala Arg Cys Phe Phe His

50

55

60

Ser Val Cys Pro Ala Gly Met Ile Val Lys
65 70

<210> 7
<211> 74
<212> PRT
<213> Homo sapiens

<400> 7
Cys Arg Lys Gln Cys Glu Pro Asp Tyr Tyr Leu Asp Glu Ala Gly Arg
1 5 10 15

Cys Thr Ala Cys Val Ser Cys Ser Arg Asp Asp Leu Val Glu Lys Thr
20 25 30

Pro Cys Ala Trp Asn Ser Ser Arg Thr Cys Glu Cys Arg Pro Gly Met
35 40 45

Ile Cys Ala Thr Ser Ala Thr Asn Ser Cys Ala Arg Cys Val Pro Tyr
50 55 60

Pro Ile Cys Ala Ala Glu Thr Val Thr Lys
65 70

<210> 8
<211> 75
<212> PRT
<213> Homo sapiens

<400> 8
Glu Cys Leu Pro Cys Gly Glu Ser Glu Phe Leu Asp Thr Trp Asn Arg
1 5 10 15

Glu Thr His Cys His Gln His Lys Tyr Cys Asp Pro Asn Leu Gly Leu
20 25 30

Arg Val Gln Gln Lys Gly Thr Ser Glu Thr Asp Thr Ile Cys Thr Cys
35 40 45

Glu Glu Gly Trp His Cys Thr Ser Glu Ala Cys Glu Ser Cys Val Leu
50 55 60

His Arg Ser Cys Ser Pro Gly Phe Gly Val Lys
65 70 75

<210> 9
<211> 34
<212> PRT
<213> Homo sapiens

<400> 9
Asp Cys Val Pro Cys Gln Glu Gly Lys Glu Tyr Thr Asp Lys Ala His
1 5 10 15

Phe Ser Ser Lys Cys Arg Arg Cys Arg Leu Cys Asp Glu Gly His Gly
20 25 30

Leu Glu

<210> 10
<211> 58
<212> PRT
<213> Homo sapiens

<400> 10
Cys Arg Pro Cys Gly Pro Gly Phe Tyr Asn Asp Val Val Ser Ser Lys
1 5 10 15

Pro Cys Lys Pro Cys Thr Trp Cys Asn Leu Arg Ser Gly Ser Glu Arg
20 25 30

Lys Gln Leu Cys Thr Ala Thr Gln Asp Thr Asp Thr Val Cys Arg Cys
35 40 45

Arg Ala Gly Thr Gln Pro Leu Asp Ser Tyr
50 55

<210> 11
<211> 69
<212> PRT
<213> Homo sapiens

<400> 11
Cys Ser Pro Cys Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg
1 5 10 15

Thr Cys Asp Ile Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys
20 25 30

Glu Cys Ser Ser Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly Phe
35 40 45

His Cys Leu Gly Ala Gly Cys Ser Met Cys Glu Gln Asp Cys Lys Gln
50 55 60

Gly Gln Glu Leu Thr
65

<210> 12
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Novel Sequence

<400> 12
Tyr Cys Glu Leu Ser Gln Tyr Leu Cys Tyr
1 5 10

<210> 13
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Novel Sequence

<400> 13
Tyr Cys Trp Ser Gln Asn Leu Cys Tyr
1 5

<210> 14
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Novel Sequence

<400> 14
Tyr Cys Trp Ser Gln Asn Tyr Cys Tyr
1 5

<210> 15
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Novel Sequence

<400> 15
Tyr Cys Trp Ser Gln Tyr Leu Cys Tyr
1 5

<210> 16
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Novel Sequence

<400> 16
Tyr Cys Phe Thr Ala Ser Glu Asn His Cys Tyr
1 5 10

<210> 17
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Novel Sequence

<400> 17
Tyr Cys Phe Thr Asn Ser Glu Asn His Cys Tyr
1 5 10

<210> 18
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Novel Sequence

<400> 18

Tyr Cys Phe Thr Arg Ser Glu Asn His Cys Tyr
1 5 10

<210> 19

<211> 9
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 19

Phe Cys Ala Ser Glu Asn His Cys Tyr
1 5

<210> 20

<211> 9
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 20

Tyr Cys Ala Ser Glu Asn His Cys Tyr
1 5

<210> 21

<211> 9
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 21

Phe Cys Asn Ser Glu Asn His Cys Tyr
1 5

<210> 22

<211> 9
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 22

Phe Cys Asn Ser Glu Asn Arg Cys Tyr

1

5

<210> 23

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 23

Phe Cys Asn Ser Val Glu Asn Arg Cys Tyr

1

5

10

<210> 24

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 24

Tyr Cys Arg Lys Glu Leu Gly Gln Val Cys Tyr

1

5

10

<210> 25

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Novel Sequence

<400> 25

Tyr Cys Lys Glu Pro Gly Gln Cys Tyr

1

5

<210> 26
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Novel Sequence

<400> 26
Tyr Cys Arg Lys Glu Met Gly Cys Tyr
1 5

<210> 27
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Novel Sequence

<400> 27
Phe Cys Arg Lys Glu Met Gly Cys Tyr
1 5

<210> 28
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Novel Sequence

<400> 28
Tyr Cys Ser Gln Ser Val Ser Asn Asp Cys Phe
1 5 10

<210> 29
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Novel Sequence

<400> 29
Phe Cys Val Ser Asn Asp Arg Cys Tyr
1 5